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Abstract: 
Background: 
Little is known about how physicians assimilate evidence regarding prostate cancer 
prevention. Finasteride, a drug studied as a chemopreventive agent for prostate cancer 
has produced controversial results. The purpose of this research design paper is to 
provide background and rationale for my proposed project to examine the current 
knowledge and use of finasteride among primary care physicians and urologists in the 
Veterans Health Administration (VHA). 
Aims: 
Specifically, I seek to a) identify trends in finasteride prescriptions in the VHA over time, 
and determine whether these trends correlate with publication of evidence or guidelines; 
b) identify trends in alpha-blocker prescriptions in the VHA over time to help determine 
that proportion of finasteride prescriptions attributable to combined treatment for benign 
prostatic hyperplasia (BPH); and c) determine the knowledge, and use offinasteride as 
well as the perceptions, characteristics and contextual factors of those physicians who are 
in a position to utilize finasteride. 
Study Design: 
A formal systematic review of the evidence pertaining to several aspects offinasteride 
use in the prevention of prostate cancer is presented. Thereafter, the first part of my 
proposed study will involve assessing time trends in prescriptions for finasteride and 
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alpha-blockers from October 1998 to December 2005 using the VHA Pharmacy Benefits 
Management (PBM) database. The second part will involve surveying VHA primary 
care physicians (PCPs) and urologists regarding their use and knowledge offinasteride. 
Hypotheses: 
I hypothesize that finasteride prescriptions will increase slowly during the late 1990s and 
early 2000s, but accelerate concomitant with the publication of the Prostate Cancer 
Prevention Trial (PCPT) and Medical Therapy of Prostate Symptoms (MTOPS) studies. 
However, prescriptions for alpha-blockers, in particular the selective alpha-blockers, will 
similarly increase. This would suggest that the overwhelming majority of increased 
finasteride use is for treatment of BPH rather than chemoprevention. I anticipate this 
finding will be confirmed in the survey when physicians indicate that they mostly use 
finasteride to treat BPH. 
However, I also hypothesize that knowledge of finasteride main effects, side-effects and 
influence on prostate parameters will be surprisingly low. I anticipate, more urologists 
than primary care physicians will be comfortable prescribing finasteride in general, and 
more urologists will report using finasteride as a prostate cancer chemopreventive agent. 
Impact: 
Given the potential impact finasteride has on prostate cancer incidence, aggressiveness 
and screening, the insight gained regarding the current use of finasteride is important. 
Discovering that many men are currently taking finasteride, but that physicians are not 
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well informed regarding the influence of finasteride on parameters such as PSA, prostate 
volume and the potential increased risk of high grade tumors may indicate a need for 
directed educational interventions for both physicians and patients. 
Understanding physician perceptions of the current evidence for finasteride as a 
chemopreventive agent will help guide future research and tailor guidelines to address the 
areas of greatest concern or uncertainty. I will gain insight into the different levels of 
knowledge and perception between PCPs and urologists. Such information could guide 
future recommendations for when PCPs should refer a patient to a urologist. 
Summary: 
The uncertainty surrounding use of finasteride to prevent prostate cancer is unlikely to be 
resolved for several years. This study will provide important information regarding how 
physicians in the VHA perceive the uncertainty and how these perceptions translate into 
use of finasteride. The VHA is uniquely positioned to study this problem and the results 
will influence future research and guideline creation. 
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Introduction 
"In health care, invention is hard, but dissemination is even harder. "1 (Donald Berwick) 
For every new piece of evidence pertaining to topics of public health importance 
much energy is spent dissecting the results, ascertaining internal and external validity and 
placing new proof in the context of existing evidence. This cycle of conjecture and 
refutation that plays out in the literature takes place among academic researchers and 
thought leaders. These opinions, distilled in editorials, meta-analyses, systematic reviews 
and clinical practice guidelines, are intended to convey consensus to the community of 
physicians facing these clinical dilemmas. 
Yet little is known about the success of this dissemination. To what degree do 
physicians access the information, assimilate the information and incorporate the 
information into practice? Furthermore, many issues in public health do not have a clear-
cut answer. Medical or biological uncertainty leads to variations in clinical practice,2 but 
we are seldom aware of the specific issues or barriers causing physicians to hesitate in 
changing their practice. 
These issues are particularly evident in the field of prostate cancer prevention. 
One in six men are destined to be diagnosed with prostate cancer in their lifetime with an 
estimated 234, 460 cases in the United States alone this year.3 While the lifetime risk of 
death due to prostate cancer is much lower (1 in 33), the burden of suffering is 
considerable for those men diagnosed and facing treatment decisions in the context of 
uncertain prognosis.3 
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The objective of this project is to understand how physicians assimilate and use 
evidence regarding prostate cancer chemoprevention. Specifically, we seek to understand 
the use and knowledge of finasteride in the chemoprevention of prostate cancer among 
primary care physicians and urologists in the Veterans Health Administration (VHA). 
Rationale 
Prevention of Prostate Cancer 
Fully understanding the dissemination of evidence for finasteride as a 
chemopreventive agent requires an understanding of the perspective of prostate cancer 
prevention and particularly chemoprevention. 
Prevention refers to any act which attempts to reduce the likelihood of bad health 
outcomes. Preventive behaviors are classified into primary prevention, secondary 
prevention and tertiary prevention. Primary prevention refers to all activities designed to 
reduce the incidence of an illness, while the goal of secondary prevention is to detect 
early disease when it is asymptomatic and when treatment is still effective. Tertiary 
prevention refers to activities that minimize further deterioration and complications of 
those who have the disease. 
For prostate cancer, several factors, when taken together, suggest that prevention 
is the optimal strategy to reduce the burden of suffering: a) the high prostate cancer 
prevalence; b) the current inability of physicians to accurately distinguish those cancers 
destined for bad outcomes from those destined for an indolent course; c) the morbidity 
associated with currently available treatments; and d) the lack of sound evidence 
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demonstrating treatment prolongs quality and quantity oflife in the U.S. setting. Every 
case of prostate cancer prevented is one fewer man who faces the uncertainty of treatment 
decisions, morbidity and prognosis. 
In prostate cancer, preventive strategies refer to the use of screening and 
chemoprevention. Screening is a form of secondary prevention, while chemoprevention 
most commonly refers to primary prevention, though it can also act as a secondary or 
tertiary preventive strategy, as shown in Figure 1. 
Figure 1: Prevention strategies to reduce burden of suffering 
Screening 
l'rimary 
Prevention 
Screening is the testing for health problems in the absence of symptoms or signs 
that would indicate the presence of the disease. The goal is to detect disease early 
enough such that treatment can eradicate the disease before the quality or quantity of life 
is affected. 
With respect to prostate cancer, screening principally refers to prostate specific 
antigen (PSA) testing and/or digital rectal examination (DRE). The U.S. Preventive 
Services Task Force, which periodically reviews the evidence regarding the benefits and 
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harms of screening, has concluded there is insufficient evidence to recommend for or 
against routine screening for prostate cancer using PSA or DRE.4 There is good evidence 
that screening with PSA can detect cancers at an early stage. 5 However, the question 
remains whether such early detection translates into improved outcomes. 
Screening is marred by several problems. First, the accuracy of the screening 
tests is suboptimal. The determination of a "normal" PSA value has come under scrutiny. 
Historically, PSA > 4.0 ng/ml was the chosen cut-off to recommend prostate biopsy. 
This has yielded sensitivities ranging from 56% to 91%, depending on the age of the 
patients and whether the study is examining aggressive cancers, low grade cancers, or all 
cancers. 6-9 PSA is more sensitive in detecting aggressive tumors. Arguments to reduce 
the cutoff to even as low as 2.5 ng/ml stem from evidence of prevalent cancer at PSA 
values much lower than 4.0 ng/ml.10 The clinical importance of cancers detected at these 
lower PSA values is not known though. DRE is less accurate and has limited 
reproducibility as compared to PSA. 11 A meta-analysis found that DRE had a sensitivity 
of59%Y 
The second problem with screening is the reference standard, prostate biopsy. 
Unfortunately, prostate biopsy has a false-negative rate ofbetween I 0 to 30% for a first 
biopsy. 13. 16 Thus, a significant proportion of men with a positive screening test will be 
falsely classified as being free of disease. Finally, once cancer is identified, the current 
parameters used to prognosticate cannot adequately distinguish those cancers destined to 
kill from those destined for an indolent course. 17.20 
The serial uncertainty in the process is multiplied and at each stage these 
uncertainties are anxiety provoking for the patient. Furthermore, screening introduces 
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physical pain and discomfort if a biopsy is warranted and subsequent treatment is 
undertaken. Thus, in the absence of clear evidence of benefit, screening cannot be 
recommended as a national strategy to reduce the burden of suffering from prostate 
cancer. 
The urological community awaits the publication of two large randomized 
controlled trials examining the efficacy of screening. The Prostate Lung Colorectal and 
Ovarian (PLCO) cancer screening trial, which is set in the United States, and the 
European Randomized Study of Screening for Prostate Cancer (ERSPC) have closed to 
accrual and will likely publish before 2010.21 •22 Until such time, it is doubtful that 
sufficient evidence will arise to significantly tip the balance in favor of, or against, 
screening for prostate cancer. 
Chemoprevention of Prostate Cancer 
Chemoprevention refers to the use of chemical agents, drugs, or food supplements 
to prevent disease. The term chemoprophylaxis has identical meaning and is used 
interchangeably in the literature but will not be used in this paper. As enthusiasm for 
prostate cancer screening wanes, hope for identifying a useful chemopreventive agent is 
peaking. Several promising agents exist. 
I performed a formal systematic review addressing the evidence pertaining to the 
most promising chemopreventive agent, finasteride. However, it is important to realize 
that other agents have similar rationale for use in a primary chemopreventive setting. 
They include selenium, vitamin E, vitamin D, NSAIDS, soy, lycopene and green tea. A 
brief review of each of these is presented first. 
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Selenium 
Selenium is an essential trace element found predominantly in grains, fish, meat, 
poultry, eggs and dairy products. 23 It enters the food chain through plant consumption 
but is also available in many over-the-counter supplements and multivitamins. Selenium 
is a constituent of many antioxidant enzymes called selenoproteins.24 Several lines of 
evidence exist supporting selenium as having a protective effect against prostate cancer. 
In vitro, selenium inhibits proliferation and induces apoptosis in prostate cancer 
celllines?5• 26 Early human case-control and cohort studies, also proved promising.27' 28 
The strongest evidence in support for selenium comes from The Nutritional 
Prevention of Cancer Trial (NPCT). This was a randomized controlled trial of 1312 
patients with non-melanoma skin cancer, 97 4 of which were male with a mean age of 64 
years. Patients received either oral selenized yeast (200ug/day) or placebo and were 
interviewed every 6 months to determine the incidence of cancer?9 All identified cancers 
were confirmed by review of medical records. No end-of-study prostate biopsy was 
performed, as prostate cancer was a secondary end-point and was added after the trial had 
commenced. 
While there was no significant impact on the primary end-point, recurrence of 
basal cell carcinoma or squamous cell carcinoma, selenium reduced the incidence of 
several cancers which were secondary end-points. The secondary end-points were added 
to the trial protocol after preliminary data began to compile showing certain benefits in 
incidence of certain cancers. In the case of prostate cancer, only data after the declaration 
of prostate cancer incidence as a secondary end-point was reported. With a mean follow-
up of 6.5 years, the incidence of prostate cancer was decreased by 63% in the selenium 
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group (RR 0.37; p=0.002).30 Though not directly reported in the original study, baseline 
risk for prostate cancer after randomization was likely slightly higher for the selenium 
group given that patients had a higher mean age (64.4 vs 63.2) and had a higher 
percentage ofmen with baseline PSA > 4.0 ng/ml (10.4% vs 9.0%). This risk reduction 
held across all strata of baseline PSA levels with the exception of those patients with> 10 
ng/ml at baseline. However this sub-group likely had indolent cancer at the time of 
emolment. A follow-up study to the NPCT reported mean follow-up to 7.45 years. The 
reduction in incidence of prostate cancer still held (RR 0.51; 0.29-0.87).31 
With studies that have added secondary end-points mid-trial, caution must be 
applied to the results. By chance, certain associations will appear in the data. For a 
prostate cancer to become "incident" the patient needs to be symptomatic in such a way 
that he seeks urologic care which, in tum results in a biopsy, or he is screened and 
subsequently referred for biopsy. Given that these men were blinded to treatment and 
that selenium is not known to affect PSA levels, the only possible explanation is that 
selenium reduces lower urinary tract symptoms and thus reduces referrals for biopsy in 
that arm of the study. No such effect has been documented. Without an end-of-study 
biopsy, or data on the number of referrals for biopsy, it is impossible to know the true 
effect of selenium on prostate cancer incidence. However, the magnitude of risk 
reduction is large and cannot be entirely explained by chance or confounding. 
VitaminE 
Vitamin E is one of the fat-soluble vitamins and functions as an antioxidant in cell 
membranes.32 Alpha-tocopherol is the predominant form in human tissues and is known 
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to moderate prostate cell growth. In vitro studies have demonstrated that it can induce 
cell cycle arrest and exhibit antiandrogenic activity similar to bicalutamide, an androgen 
receptor antagonist. 33• 34 
In human studies, the largest trial to date examining the preventive role of 
Vitamin E in prostate cancer is the Alpha-Tocopherol, Beta-Carotene Cancer Prevention 
Trial (ATBC).35 This randomized controlled trial of29,133 male smokers aged 50-69 
given either vitamin E, beta-carotene, both or neither evaluated the incidence and 
mortality oflung cancer as the primary end-point.36 Prostate cancer incidence and 
mortality was one of many planned secondary endpoint analyses. Those taking 
supplemental vitamin E had a significantly lower incidence of prostate cancer (RR 0.66; 
95% CI, 0.44-0.94) and lower prostate cancer-specific mortality (RR 0.59; 95% CI 0.35-
0.99). Given that this was one of many secondary analyses, there is a possibility that this 
finding could be due to chance. Furthermore, baseline prostate cancer risk data between 
groups was not complete, and since randomization was done by geographically defined 
blocks, there could be underlying risk differences between the groups in this study. 
A more recent publication followed the ATBC cohort 6 years after termination of 
the trial. The apparent effect of alpha-tocopherol on prostate cancer incidence seen 
during the trial was considerably attenuated and no longer reached statistical significance 
with longer follow-up: RR 0.88 (95% CI 0.76-1.03).37 It is possible that vitamin E exerts 
its anticancer effects at a late stage of carcinogenesis and in a transient fashion. Thus, 
shortly after stopping the drug, the late stage neoplastic changes progress to 
malignancies. It is clear that further information is needed to sort out the true effect, if 
any, of alpha-tocopherol on prostate cancer incidence. 
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SELECT TRIAL 
The cumulative findings of the potential preventive role of both vitamin E and 
selenium formed the rationale for the large Selenium and Vitamin E Cancer Prevention 
Trial (SELECT).38 In particular, in vitro studies demonstrating synergy between vitamin 
E and selenium in augmenting apoptosis prompted incorporating both nutrients into the 
study design.39 This NCI sponsored phase III RCT tests the use of selenium and vitamin 
E alone, and in combination, in the prevention of prostate cancer. Men were eligible to 
participate in this two-by-two factorial design trial if they were older than 55 years of age 
(or 50 for African American men (AAM)), had a negative DRE and a PSA <::;4 ng/ml and 
normal blood pressure. The SELECT trial accrued more than 35,534 men from over 400 
sites in the U.S., Canada, and Puerto Rico.38• 4° Furthermore, it has enrolled 21% 
minorities, including 15% AAM, which is three fold more than other large prostate 
cancer prevention trials have accomplished (PCPT: 4% AAM;41 REDUCE: 2% AAM42). 
The primary endpoint in the SELECT study is clinical incidence of prostate 
cancer. No end-of-study biopsies will be performed. Unlike the use of finasteride in the 
PCPT, no PSA adjustment is needed in SELECT as vitamin E and selenium are not 
known to have a direct effect on PSA production. This reduces the biases inherent in 
using incident cancers rather than period prevalent cancers. Secondary endpoints include 
prostate cancer survival, all cause mortality and the incidence and mortality of other 
malignancies. Prostate cancer survival may be subject to differential lead time bias if use 
of selenium and vitamin E promoted the early detection of prostate cancer. However, 
there is no evidence to support such a bias. The study is powered to detect a 25% 
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reduction in the incidence of prostate cancer for either selenium or vitamin E. However, 
it has sufficient power to detect an additional 25% reduction attributable to the 
combination of selenium and vitamin E. The results of this trial are anticipated in 2013. 
VitaminD 
Vitamin D has received interest as a chemopreventive agent for prostate cancer. 
It is hypothesized that 1,25-dihydroxycholecalciferol (1,25(0H)2D3), or the active form 
of vitamin D, plays an important role in inhibition of tumor growth and metastasis.43 In 
vitro, exogenous administration of 1,25(0H)2D3 to prostate cancer cells halts 
proliferation.44 This hypothesis has been supported, though inconsistently, by several 
epidemiological studies. These observations were thoroughly reviewed recently,45 and 
they include: a) men receiving less sun exposure, such as those living in northern 
latitudes, have lower levels of vitamin D and a higher mortality rate from prostate cancer; 
b) prostate cancer occurs more frequently in older men, in whom vitamin D deficiency is 
more common; c) AAM, whose increased levels of melanin in the skin blocks ultraviolet-
induced production of vitamin D, have the highest incidence and mortality from prostate 
cancer in the world; d) native Japanese men, whose diet is rich in vitamin D, have a low 
incidence of prostate cancer; and e) dietary intake of calcium-rich products, which 
suppresses vitamin D levels, are associated with higher risk of prostate cancer. 
This latter finding is supported by two large prospective cohort studies. The 
Cancer Prevention Study II Nutrition Cohort studied 65,321 elderly U.S. men with mean 
age ranging from 63 to 66 yrs (depending on the tertile of calcium intake) and gathered 
detailed questionnaire data on diet, medical history and lifestyle at enrolment.46 Total 
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calcium intake was associated with a modest increase in prostate cancer risk (RR 1.2; 
95% CI 1.0-1.6) adjusted for education, family history of prostate cancer and total energy 
intake. A dose-response relationship was noted between calcium intake and prostate 
cancer risk (p=0.02 for trend). The Health Professionals Follow-Up evaluated 47,781 
men from 1986 to 1994 and found a stronger association.47 The highest tertile of calcium 
consumption compared to the lowest was associated with increased total prostate cancer 
(RR 1.71; 95% CI 0.94-3.19), advanced prostate cancer (RR 2.97; 95% CI 1.61-5.50) and 
metastatic prostate cancer (RR 4.57; 95% CI 1.88-11.1). 
Taken together, these studies provide some indirect evidence for a protective 
influence of vitamin Don prostate cancer. However, use of vitamin D anaologs has been 
limited by their hypercalcemic effects.48• 49 Newer analogs with more specificity are 
currently being tested and may provide another chemopreventive strategy for prostate 
cancer. 5° 
Other chemopreventive possibilities 
Several other chemopreventive strategies have emerged. Cyclooxygenase-2 
(COX-2) inhibitors are currently being studied. It is known that prostate cancers express 
more COX-2 than benign tissue, and that this overexpression is associated with decreased 
apoptosis,51 increased angiogenesis, 52 and immunosuppression. 53 Thus, rationale exists 
for a potential role for COX-2 inhibition in the prevention or inhibition of prostate cancer 
carcinogenesis. However, epidemiologic studies examining the association between 
prostate cancer incidence and use ofNSAIDS are conflicting. 54 
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The role of soy in prostate cancer stemmed from the observation that eastern 
countries, where soy plays an important role in traditional diets, have lower rates of 
prostate cancer, while western countries, where soy plays a minimal role in our diets, 
have higher rates of prostate cancer. A recent case-control study involving 133 prostate 
cancer cases and 265 age-matched controls from China demonstrated a protective effect 
associated with soy consumption (OR 0.51; 95% CI 0.28-0.95).55 In vitro studies have 
shown that soy and its components and their metabolites inhibit benign and malignant 
prostatic epithelial cell growth, downregulate androgen-regulated genes, and reduce 
tumor growth. 56' 57 
Lycopene, found primarily in tomatoes and other red fruits and vegetables, 
possesses potent antioxidant activity. In vitro, lycopene inhibits growth of benign and 
malignant prostatic epithelial cells. 58 Yet, epidemiological evidence regarding the 
association oflycopene consumption and prostate cancer risk is mixed.59.61 
Finally, green tea has been studied in vitro or in animal models only. Similarly 
based on the observation that men from Asian countries have lower incidence of prostate 
cancer and substantially higher consumption of green tea, the polyphenols contained in 
green tea have been scrutinized. The major constituent has been shown to induce 
apoptosis and inhibit cell-growth,62 and in the mouse has been shown to inhibit tumor 
development and metastasis. 63 
Finasteride: a review ofthe evidence 
Background 
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The most promising agent and the one that has received the most interest oflate 
is finasteride. Finasteride inhibits the enzyme S-a-reductase type 2, which is found in 
two locations in the body: the prostate and genital skin. Here, it catalyzes the conversion 
of testosterone to dihydrotestosterone (DHT). In serum, DHT concentrations are one-
tenth that of testosterone; in prostatic tissue, DHT is several times higher in 
concentration.64•65 Furthermore, it is known that DHT is 8 to 10 times as potent as 
testosterone. The importance ofDHT is seen in a large cohort living in Dominican 
Republic where the incidence of S-a-reductase type 2 deficiency is high. The males in 
that population have only a rudimentary prostate without epithelium, an undetectable 
PSA and no development of either benign prostatic hyperplasia or prostate cancer.66 
DHT is thought to be a promoter of the development of prostate cancer, thus 
reducing the concentrations ofDHT within the prostate may reduce the genesis of 
neoplasia.67 In vitro, finasteride has been shown to inhibit growth of prostate cells.68• 69 
In vivo, men treated with finasteride for BPH experienced a 50% reduction in PSA and a 
20% decrease in gland volume.7° Finally, physicians, both primary care and urologists, 
as well as patients have familiarity with finasteride from its role in treating BPH. The 
safety and side-effect profile is well accepted. 71• 72 Thus, there is good rationale to test 
whether finasteride may reduce the incidence of prostate cancer. 
In this section, a systematic review was conducted to address the evidence 
pertaining to finasteride in preventing prostate cancer. 
Methods 
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I developed 6 key questions that address the important issues surrounding the use 
of finasteride as a chemopreventive agent. The overarching question, or Key Question 
# 1, asks: Does daily use of finasteride reduce the incidence of prostate cancer? The 
target population is average risk men >45 yrs of age with life expectancy> 1 Oyrs. 
Though preventive strategies, on the whole, focus on reducing the incidence of 
bad outcomes such as mortality, I chose this specific question for two reasons. First, as I 
argued above, the majority of the burden of prostate cancer stems not from mortality but 
from the psychological and physical side-effects of being diagnosed and treated. Thus, 
the first and most important step in reducing this burden would be to reduce the incidence 
of the disease. Second, a systematic review addressing the question of whether 
finasteride reduces prostate cancer mortality would require an indirect analytic approach 
and a very involved review that is outside the scope of this masters paper. 
The six key questions used in the analysis are listed here: 
Key questions: 
1) What is the efficacy of finasteride in preventing the incidence of prostate cancer? 
2) What harms are associated with using finasteride as a chemopreventive agent for 
prostate cancer? 
3) What is the effect of finasteride on the performance of currently used screening tests 
(DRE, PSA) or prostate biopsy? 
4) What costs are associated with using finasteride in every male patient within the 
defined population to prevent prostate cancer? 
5) Have studies modeled the potential benefits of using finasteride to prevent prostate 
cancer? 
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6) What is the cost-effectiveness of using finasteride to prevent prostate cancer? 
With the 6 key questions established, I systematically searched MEDLINE, 
EMBASE, CINAHL and Cochrane databases from January 1988 to September 15,2002, 
using the Medical Subject Headings "prostate neoplasms" or "prostate" and combining 
these terms with predefined terms for each of the key questions to identifY English 
language studies concerning the 6 key questions. Additionally hand searches of review 
bibliographies were conducted. The complete search strategy is defined below. 
The start date was chosen for two reasons. First, the first published article 
mentioning finasteride use in humans was in 1988 and finasteride was not approved by 
the FDA until1992. Second, the PSA era did not begin until this time. Thus, results 
from prostate cancer epidemiological studies before this era may not apply to cancers 
seen presently. 
The following inclusion criteria were used in identifYing appropriate articles: (1) 
randomized controlled trials (RCTs), secondary analyses ofRCTs, case-control studies, 
and ecologic studies that examined links between using finasteride and reduced prostate 
cancer incidence; (2) studies that addressed changes in prostate cancer biology, 
presentation, behavior or the performance of screening tests secondary to finasteride 
exposure; (3) studies with patient reports about their experience (especially side effects) 
with taking finasteride; and ( 4) studies that examined or modeled the costs and benefits of 
using finasteride to prevent prostate cancer. 
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Papers pertaining to the following were excluded: papers at the basic science level 
with non-clinical outcomes, and papers involving men who have already been diagnosed 
with prostate cancer. 
From the list of titles generated by searches of each database, I chose titles that 
may apply to the key questions. At this stage, I emphasized sensitivity rather than 
specificity. That is, if in doubt, I included a title. Next, I reviewed the abstracts for the 
chosen titles and selected all articles that met eligibility criteria. Data from the chosen 
articles were then abstracted using a standardized form (Appendix I). In addition to 
abstracting the setting of the study, the patients involved, the intervention(s) used, 
measures of exposure and outcome, results and conclusions, I also graded the quality of 
all included articles according to criteria established by the USPSTF in their review 
series.73 
The most sensitive search, which I have termed the primary search, combined the 
key words "prostate neoplasms", "prostate" and "finasteride". Limiting this search to 
"English langnage" and "humans" yielded 300 titles. From these 300, 56 were chosen as 
possibly pertaining to any of the 6 key questions. To ensure that no papers were missed 
within each key question, additional secondary searches were performed combining the 
terms "prostate neoplasms" and "prostate" in series with key words in table 1 below: 
Table 1: MeSH headings used to search specific key questions 
Finasteride/adverse effects/*therapeutic use 
Humans 
Male 
[Middle aged 
Azasteriods/therapeutic use 
Testosterone 5 alpha reductase/*aotagonists and inhibitors 
Enzyme inhibitors/*therapeutic use 
Antineoplastic agents, hormonal/adverse effects 
*therapeutic use 
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Cost and cost analysis 
Cost-benefit 
Cost-effectiveness 
Biopsy 
Morbidity 
Neoplasms, hormone-dependent/prevention & control 
Prostate specific antigen/blood 
Prostate/pathology 
Adenocarcinomoa/*prevention & control 
From the secondary searches, 1098 titles were identified however, only 3 more 
unique titles were identified that met inclusion criteria. This low number is a result of the 
considerable overlap between the primary search and all of the secondary searches. This 
illustrates how inclusive the primary search was. Finally, hand-searches of review 
articles identified before the formal literature search yielded 2 additional unique titles and 
were included for review. 
Figure 2 illustrates the selection procedure for the first and most inclusive search 
described above. 
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Figure 2: Results of literature searches 
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Articles identified as pertaining to any of the 6 key questions were then ear-marked to the 
appropriate key question. Some papers provided information on more than one key 
question. Table 2 illustrates the number of articles identified for each key question. 
Questions 4 to 6, because of their similarity, are grouped together in the table and also 
during data abstraction. 
Table 2: Full-text articles reviewed for each key-question 
4) What costs are associated using in every 
defmed population to prevent prostate cancer? 
5) Have studies modeled the potential benefits of using fmasteride to prevent 
prostate cancer? 
What is the cost -effectiveness finasteride to cancer? 
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Key Question #1: What is the efficacy offinasteride in preventing the incidence of 
prostate cancer? 
Of all the chemopreventive agents studied in prostate cancer, finasteride has the 
largest volume and highest quality of evidence addressing the question of whether its use 
reduces the risk of prostate cancer. The Prostate Cancer Prevention Trial (PCPT) in 
particular, is a large, recent and good quality randomized controlled trial that has assessed 
this question directly.41 Before discussing this trial in detail, evidence from other studies 
pre-dating the PCPT will be discussed. 
Before publication of the PCPT, data were conflicting regarding the benefits of 
finasteride in preventing prostate cancer. However, all studies were of poor quality, as 
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outlined in Appendix 1, Key Question I. A nested case-control study set in France 
examined 639 men with prostate cancer and compared them to 659 men without prostate 
cancer.74 These men were chosen consecutively from patients referred to 12 French 
urological centers for prostate biopsy. Medication usage was assessed through patient 
self report. Comparing those who had ever used finasteride to those who had never used 
finasteride, the odds ratio for developing prostate cancer was 0.58 (95% CI 0.37-0.92) 
adjusted for age, ethnic origin, family history of prostate cancer, investigator center, use 
ofNSAIDs, BMI, history of farming, red meat, poultry, fish and wine consumption. 
However, this study has several fatal flaws. The median time of exposure to finasteride 
was only 12 months, with some men reporting taking finasteride for only 1 month. Men 
categorized as having ever taken finasteride included men who reported taking it fewer 
than once per month. Both of these question the observed protective effect of finasteride 
in this study since such short and inconsistent exposure to finasteride would be unlikely 
to translate into reduced cancer risk. Finally, this population was not average risk; these 
were all men referred for biopsy. This is confirmed by their median PSA levels of 12.2 
ngiml among those with cancer and 7.9 ngiml among those without cancer. 
In contrast, a pooling of results of 1,645 men from 2 RCTs offinasteride in the 
treatment of BPH showed that there was no difference in the detection of prostate cancer 
among those taking finasteride (0.7% vs 0.7%, no statistics performed). However, no 
regimented pre-study biopsies were performed, and patients were only on finasteride for 
12 months before their end-of-study biopsies. Thus, the cancers detected are more likely 
to represent cancers present before the study rather than effects of the study drug. 
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The Prostate Cancer Prevention Trial (PCPT) 
Amidst the established biological plausibility but absent good quality evidence, in 
1992, the large randomized controlled PCPT opened to accrual to test whether taking 
finasteride daily for seven years would reduce the incidence of prostate cancer. This 
good quality trial directly addresses key question #1 and as such, is discussed in detail. 
The objective of the PCPT was to determine whether finasteride can reduce the 
period prevalence of prostate cancer among initially healthy men during a seven-year 
period. The term "period prevalence" was used in the trial rather than "incidence" as it 
more accurately depicts that many cancers were identified by end-of-study biopsy in men 
who would not have otherwise been biopsied during the 7 year period. Men, aged 55 
years or older with a normal digital rectal examination (DRE), no clinically significant 
coexisting conditions, and an American Urological Association symptom score ofless 
than 20 were recruited.75 A 3-month placebo run-in was performed. At the conclusion of 
the run-in, a PSA was drawn. If the PSA was less than 3.0 ng/ml and adherence during 
the run-in period was satisfactory, then men were randomized to receive either 5mg of 
finasteride daily or placebo. Men underwent yearly PSA measurements and digital rectal 
examination. Every six months, men were seen for prescription renewal, pill counts, and 
evaluation of clinically significant medical conditions and side effects. Every 3 months 
the men were contacted by telephone to identify any interim medical events. At the end 
of the study, all men who had not received a diagnosis of prostate cancer were offered an 
end-of-study prostate biopsy. PSA levels were determined by a central laboratory and 
reported back to the clinicians caring for the patients. Because finasteride is known to 
cause a decrease in PSA, 76 the actual PSA values reported back to the clinicians was 
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adjusted such that the biopsy rate in the finasteride ann would approximate those in the 
placebo ann. For years 1-3, the PSA was doubled. As men entered their fourth year in 
the study, their PSA values were multiplied by a factor of2.3. Triggers for biopsy 
included a PSA level (or adjusted PSA level for the finasteride group)> 4.0ng ml or an 
abnormal digital rectal examination. Biopsies were performed transrectally with the 
assistance of transrectal ultrasound (TRUS). 
In total, 24,482 eligible men were enrolled, and 18,882 underwent randomization. 
The majority of men (71 %) were excluded because their PSA values were above 3.0 
nglml. Information regarding why others were excluded is not given. The study was 
stopped early by the Data Safety and Monitoring Committee (DSMC) because it was felt 
that additional data were highly unlikely to change the study outcome. At the time of 
publication, 86.3% of men had completed the full 7 year protocol. Only men with 
complete follow-up information were included. Thus, those who died before undergoing 
a for-cause or end-of-study biopsy (1123), those lost to follow-up before undergoing a 
for-cause or end-of-study biopsy (1256), and those refusing an end-of-study biopsy 
(3927) were not included in the analysis. 
With the primary end-point of prostate cancer period prevalence, men in whom 
prostate cancer status was not known could not be included in any analyses. If the end-
point was incidence rate then these men could contribute person-time. Thus, only 9,060 
men, or 48% of the initial18,882 men randomized were included in the final analysis. 
The study states that an intention to treat (ITT) analysis was performed on these 9,060 
men. While calling this an ITT analysis would be inappropriate if the outcome were 
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incidence rate, it is fair to consider this an ITT analysis among men with known prostate 
cancer status. 
The main finding of the study was that prostate cancer was detected in 18.4% of 
the finasteride group and 24.4% of the placebo group (RRR 24.8%; 95% CI 18.6-30.6; 
p<0.001). This translates into a number needed to treat (NNT) of 17. In other words, 17 
patients would need to be treated with finasteride 5mg for 7 years in order to prevent one 
case of prostate cancer. The risk reduction was similar across risk groups as defined by 
age, race, family history and strata ofPSA at baseline. 
For cause biopsy was recommended to 22.5% ofthe finasteride group and 24.8% 
of the placebo group (p<0.001) after adjusting the PSA results for the finasteride group. 
The DSMC adjusted the PSA levels such that the rate ofbiopsy recommendations would 
be equal between the two groups. The degree to which recommendations for biopsies 
were followed by patients was found to be related to PSA level in the placebo group, but 
not in the finasteride group. 
Adherence was fair, with 10.8% of days of treatment missed in the placebo group 
and 14.7% of days missed in the finasteride group. Additionally, serum DHT levels were 
measured in a random sample of 5% of patients to ascertain adherence in the finasteride 
group and a measure of drop-in rate in the placebo group. The percent with DHT levels 
above 16 ng/ml (suggesting non-adherence) in the finasteride group was 14.5%, the 
percent with DHT levels below 16 ng/ml (suggesting drop-ins) in the placebo group was 
6.5%. 
In summary, despite the early conflicting evidence from poor quality studies, the 
large, good quality randomized controlled PCPT answers the first key question directly. 
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Finasteride can be used to reduce the period prevalence of prostate cancer. Whether it 
should be used requires answering key questions 2 through 6. 
Key Question #2: what harms are associated with usingfinasteride as a chemopreventive 
agent for prostate cancer? 
Side-effects and adverse events warrant particular consideration in evaluating a 
chemopreventive agent since the drug will be given to healthy, or average risk men. 
Information on the side-effects oflong term finasteride use can be gleaned directly from 
the PCPT or indirectly from trials of finasteride in the treatment of BPH. 
Side-effects: 
The Medical Therapy of Prostate Symptoms (MTOPS) trial and the Proscar Long-
term Efficacy and Safety Study (PLESS) were randomized controlled trials involving 
finasteride in the treatment ofBPH.71 • 77 The MTOPS study compared 3047 men over the 
age of 50 with BPH symptoms ranging from mild to severe. Men were randomized to 
receive the alpha-blocker doxazosin, finasteride 5mg, the combination, or placebo for 4 
years. In PLESS, 3040 men were randomized to receive 5mg of finasteride or placebo 
for 4 years. 
While the primary outcomes related to clinical progression ofBPH (MTOPS) and 
changes in symptom scores (PLESS), side-effect data were collected through physician 
interview repeatedly during the study period. Side-effect data were similarly collected by 
physician interview in the PCPT. As such, for these three trials, reported side-effect rates 
may be underestimates as physician-reported symptoms often underestimate the 
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incidence relative to patient reported. However, such bias should be present across the 
treatment and control groups given adequate masking and thus should not affect risk 
estimates. 
Direct comparisons of incidence of side-effects are difficult given the varying 
side-effects recorded, the units of measure (incidence density versus cumulative 
incidence) and differences in the duration of study. Table 3 summarizes the observed 
incidences and rates for the four most common side-effects observed in those on 
finasteride. 
Table 3: Summary of incidence and incidence density of tbe most common side-effects associated 
with finasteride use 
Breast N/A N/A 0.1% 0.4-0.5%* 2.8% 4.5%* 1.61-5.00 
T endemess or 
as rates per person-years (incidence 
€ = data reported after year I of the study, reported as % of patients 
6 = data reported as cumulative incidence at 7 years, reported as % of patients 
1'!. =includes decreased ejaculate and abnormal ejaculate 
o = shown as a range of the smallest to the largest risk (or rate) ratio calculated from each trial 
* = p<0.05 for comparison between fmasteride and placebo group 
The overall risk ratio reported in the table was obtained by calculating the risk 
ratio (or rate ratio in the case ofMTOPS) for each individual study. The highest and 
lowest individual risk ratio is reported as a range. Overall, finasteride is associated with 
statistically significant decreases in libido and erectile function as well as ejaculate 
abnormalities and breast tenderness or enlargement. 
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Additionally, the PCPT found that despite the increase in sexual side-effects listed 
above, those treated with finasteride had less urinary urgency and frequency (12.9% 
finasteride vs 15.6% placebo), prostatitis ( 4.4 vs 6.1 %), urinary tract infections (1.0 vs 
1.3%) urinary retention (4.2 vs 6.3%), diagnoses ofBPH (5.2 vs 8.7%) and transurethral 
resections of the prostate (1.0 vs 1.9%); p<0.001 for all comparisons. This is in keeping 
with the understanding that finasteride reduces prostate volume. The PCPT found that 
prostate sizes, as evaluated at biopsy, were 24% smaller in the finasteride group (mean 
volume: 25.5 cm3 in the finasteride group vs 33.6 cm3 in the placebo group). MTOPS 
found that those receiving finasteride, either alone or in combination with an alpha 
blocker, had a median 19% decrease in prostate size, while those on placebo or alpha 
blockers alone had a median 24% increase in prostate size over the 7 year study 
(p<0.001). Similarly, in PLESS, men treated with finasteride experienced a mean 18% 
decrease in prostate volume, while the placebo group had a 14% increase (p<0.001) 
Two other studies were identified that addressed the question of side-effects of 
finasteride treatment in the average risk population. However, these were deemed only 
fair quality and as such were not included in table 3 above. One study which pooled data 
from 2 RCTs that continued in open extension format for 6 years revealed identical side-
effect patterns described above.78 However, less than 50% of the originally randomized 
cohort was used in this analysis. It was not made clear who these men were, or how their 
baseline risks compared. Thus, the potential for selection bias was large. Despite 
arriving at similar results, unlike PCPT, MTOPS and PLESS, their instruments for 
measuring side-effects and symptoms were not validated. The final study was small in 
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number (n=297) and short in duration {12-months)?9 However, it revealed a similar side-
effect profile as above. 
Adverse Events 
In all studies, no deaths were attributed to the use of finasteride. Thus, the two 
main categories of adverse events include a) incident breast tumors; and b) incidence of 
high grade prostate cancers. 
There is biologic plausibility that finasteride may increase the risk of breast 
cancers in men by altering the ratio of dihydrotestosterone to estrogen in serum.80 
Concern was raised after MTOPS showed that 4 of the 1554 men receiving finasteride, 
either alone or in combination with doxazosin, developed breast cancer. Though this 
number is small, this rate is nearly 64 times that of the general population. 81 However, in 
examining PLESS data, no men taking finasteride were diagnosed with breast cancer, 
while 2 men on placebo were. Similarly, the PCPT which had over 9,000 men on 
finasteride for 7 years only had 1 man diagnosed with breast cancer. Thus, it appears the 
balance of evidence does not support an association between finasteride and breast 
cancer. 
The key secondary endpoint ofthe PCPT was the proportion of high grade, or 
aggressive tumors found in each arm of the trial. There was a higher proportion of 
tumors with Gleason grades 7 or higher in the finasteride group than in the placebo group 
(37.0% vs 22.2%; p<0.001; RR 1.67 95% CI 1.44-1.93).41 Thus, the number needed to 
harm (NNH) is 7. That is, 7 men need to be treated with finasteride for 7 years to have 1 
case of high grade cancer diagnosed. Examining men who only underwent for-cause 
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biopsies, which approximates cancers diagnosed in North America more closely than 
end-of-study biopsies, the disparity in rate of high-grade disease was greater: 47.8% had 
Gleason 7 or higher cancer in the finasteride group versus 29.4% in the placebo group 
(p<O.OOl; RR 1.63, 95% CI 1.37-1.93). The NNH in this case is 6. This issue will be 
addressed specifically in a later section entitled, "Issues raised by the PCPT". 
In summary, good quality evidence exists showing that finasteride use is 
associated with an increased incidence of sexual side-effects, but a lower incidence of 
lower urinary tract symptoms. Of greatest concern is that finasteride appears to be 
associated with high grade prostate cancer. 
Key Question #3: what is the effect offinasteride on the performance of currently used 
screening tests (DRE, PSA) or prostate biopsy? 
PSA 
As discussed previously, the merits of screening for prostate cancer are debated. 
The USPSTF has concluded there is insufficient evidence to recommend for or against 
screening. However, screening remains prevalent.82 Thus, it is imperative to know how 
finasteride influences PSA and DRE, tests currently used to screen for prostate cancer. 
Secondarily, understanding how finasteride affects these tests will provide insight into 
potential biases present in the PCPT. 
Several good quality studies, including the large RCTs, PCPT and MTOPS, have 
shown finasteride reduces PSA by approximately 50%.41 ' 77• 83• 84 The time course for this 
reduction is less well known. A study which pooled data from 2 RCTs involving 
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finasteride in men with either BPH or BPH and prostate cancer, drew PSA tests on days 
1, 2, 7, 14 and months 1, 2, 3, 4, and 6. They found, on average, PSA nadir was reached 
around the 12'h week after starting finasteride treatment.85 This was not a main outcome 
of the study and by diluting the study population with men with prostate cancer, the 
accuracy of this estimate is not clear. It has been shown that the reduction in PSA among 
men with prostate cancer treated with finasteride is less. Kaplan et a!., in a trial of 38 
high-risk men with 2 prior negative biopsies challenged with finasteride for 1 year 
showed that the mean decrease in PSA among those who went on to be diagnosed with 
cancer at the 1 year end-of-study biopsy was less than those who remained cancer free 
(28.8% decrease vs 41.0%; p=0.03).86 Though this study was conducted in a high-risk 
population that may not apply to our population of interest, this raises the possibility that 
there may be effect measure modification in the influence of finasteride on PSA among 
men harbouring cancer. Such interaction could preserve the screening or diagnostic 
utility ofPSA in the setting oflong-term finasteride treatment. 
Andriole et a!., performed a secondary analysis of the PLESS data analyzing the 
performance of PSA in predicting prostate cancer while under the influence of 
finasteride. Details of the PLESS trial were discussed above. For the first 4 years, 
investigators were not made aware of PSA test results, but were informed if patients 
surpassed a priori defined thresholds (PSA increased >0.5 from baseline for finasteride 
treated patients, or 2.0 from baseline for patients on placebo). After four years, 
investigators received the adjusted PSA results only, similar to the PCPT algorithm. 
Prostate biopsies were offered to men with PSA > 4.0 ng/ml. Those with PSA values 
>4.0 ng/ml with a negative biopsy during the study, were offered an end-of-study biopsy 
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as well. Cancers detected at biopsies triggered by elevations in PSA accounted for the 
same percentage of total prostate cancer cases in the finasteride group as in the placebo 
group (35% finasteride vs 34% placebo; p value not given). Area under the receiver 
operator curves for PSA (placebo) and PSA x 2 (finasteride) showed no significant 
differences (0.84 placebo vs 0.79; 95%CI difference: -0.005, +0.118; p=0.07).76 Using a 
PSA cut-off of 4.0 ng/ml (accounting for multiplying by two in the finasteride group) 
applied to the final PSA before diagnosis, similar sensitivities were found (66% 
finasteride vs 70% placebo, p=0.6) but higher specificity for the finasteride group was 
shown (82% vs 74%, p<O.OOl). The performance characteristics ofPSA in the setting of 
finasteride may even be more desirable than in the placebo setting. A slight decrease in 
sensitivity with an increase in specificity may mean fewer unnecessary biopsies and 
fewer cancers detected that would have remained indolent. 
Most studies conclude multiplying PSA by a factor of two for anyone on 
finasteride longer than 6 months is appropriate. A recent study by Etzioni et a!., showed 
that this multiplicative factor actually needs to increase gradually with duration of time 
on finasteride. 83 This secondary analysis of the PCPT data showed that to make the 
median PSA of men not destined to have cancer during the 7 year trial be equal in the 
finasteride and placebo arms, the multiplier needed to increase gradually from 2 to 2.5 
over 7 years. This study also showed that even without this multiplicative factor, the 
velocity ofPSA among men taking finasteride but destined to be diagnosed with cancer 
was significantly higher than in men not destined to be diagnosed with cancer. This 
suggests that PSA velocity may remain an important predictor of cancer in the setting of 
finasteride. 
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In summary, it appears appropriate to multiply the PSA by 2 in men treated with 
finasteride for longer than 3 to 6 months. It may even be appropriate to increase this 
multiplier up to 2.5 with longer durations of finasteride consumption. Most importantly, 
it appears that finasteride does not hinder the performance characteristics PSA as a 
screening test. 
DRE 
To date, no study has addressed the effect of finasteride on the sensitivity and 
specificity ofDRE. Argument could be made for finasteride either improving or 
hindering the utility ofDRE. By reducing the overall volume of the prostate by 25% on 
average, finasteride may dampen the ability to detect nodules. Alternatively, by 
shrinking the non-malignant portion of the gland, the neoplastic nodule could become 
more discernible. Data on the performance ofDRE is available in the PCPT database and 
likely would be able to answer this question. 
Biopsy 
Prostate biopsy provides information on the presence or absence of cancer, as 
well as the grade. Finasteride may affect both of these: a) it may increase the detection of 
cancer; b) it may distort the Gleason grade assigned to the cancer. 
No study has quantified the impact of finasteride on the sensitivity of prostate 
biopsy. Intuitively, by decreasing the non-malignant volume of the gland on average 
25%, this would increase the likelihood of sampling a cancer, if present. With respect to 
cancer grade, a retrospective cohort of 48 men who were taking finasteride for > 6 
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months, had biopsy proven prostate cancer and went on to have RP attempted to address 
this question. Freedom from recurrence was predicted using validated nomograms which 
incorporate Gleason grade. When the biopsy Gleason grade was used in estimating 5 
year progression-free survival, the estimated survival was not significantly different from 
the actual survival observed.87 This suggests the predictive ability of biopsy Gleason 
score is not altered by finasteride. However, this result should be interpreted with 
caution. The 5 year progression-free survival is a surrogate marker only for longer term 
outcomes. Furthermore, their mean follow-up was only 33.5 months, suggesting that few 
men contributed to this 5 year progression-free survival statistic. Finally, given the 
retrospective and uncontrolled nature of the study, the potential for selection and 
confounding bias renders the internal validity of this study low. 
There may also be interaction between detection of cancer, gland size and grade. 
The details of this will be discussed in the next section on issues raised by the PCPT. 
In summary, there is insufficient evidence to assess the influence of finasteride on 
the performance of prostate biopsy in the diagnosis of prostate cancer. 
Key Question #4: what costs are associated with usingfinasteride in every male patient 
within the defined population to prevent prostate cancer? 
Key Question #5: have studies modeled the potential benefits ofusingfinasteride to 
prevent prostate cancer? 
Key Question #6: what is the cost-effectiveness of usingfinasteride to prevent prostate 
cancer? 
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Issues raised by the PCPT 
Much of the evidence for key questions 4 through 6 attempts to address many 
controversial issues and areas of potential bias raised by the PCPT. These issues are 
discussed here prior to reviewing the evidence for key questions 4 through 6. 
The main finding of a 25% reduction in the period prevalence coupled with a 
67% increase in gleason 7 or higher tumors raised several issues. 
Differences between the finasteride and placebo arms in incidence of prostate 
cancer suggest finasteride may have treated subclinical microscopic disease. The fact 
that the difference persisted and even increased suggests that it also prevents or delays the 
onset of cancer. Though the overall cancer status ascertainment was less in the 
finasteride group (59.6% vs 63% in the placebo group), this difference unlikely 
contributed to the difference seen between the two groups in terms of prostate cancer. 
This discrepant ascertainment sterns from three trends observed in the trial: a) fewer 
abnormal DREs were detected in the finasteride group leading to fewer recommendations 
for biopsy; b) due to the effects offinasteride on prostate volume, fewer transurethral 
resections of the prostate were performed; c) more end-of-study biopsies were refused in 
the finasteride group which could also be attributed to fewer lower urinary tract 
symptoms among the finasteride group. 
Cancer was detected in 24.4% of patients in the placebo group. This figure is 
approximately 4 times the rate typically seen in other screening trials,88• 89 and more 
closely approaches the 25 to 30 percent rate of prostate cancer seen in autopsy specimens 
of men older than 50 years.90.93 Of men who had a biopsy driven only by elevated PSA 
or abnormal DRE, the rate of cancer detection approximated that seen in other screening 
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trials ( 6% ). This calls into question the clinical significance of the cancers detected in 
this study. The study promotes early detection of potentially insignificant tumors through 
two mechanisms: a) through an intense screening mechanism of yearly PSA values and 
DREs; and b) by offering a biopsy to everyone at the end of study in the absence ofPSA 
or DRE abnormality. 
The use of period prevalence as an end-point and end-of-study biopsies to 
accurately obtain this end-point was a calculated decision by the PCPT investigators. 
The risk of identifying asymptomatic tumors of unknown clinical significance was 
deemed a necessary side-effect to eliminating the multiple detection biases introduced by 
finasteride. 94 In defense of their end-point, PCPT investigators caution conclusions based 
only on for-cause biopsies because of the large number of known and potential biases that 
worked for and against finasteride. Among these biases, the reduced PSA levels, 
potential altered DRE sensitivity, oversampling of smaller glands, nonadherence to 
treatment, and differing transurethral resection of prostate (TURP) prevalence are most 
likely to be operational. 
Increased Grade: fact or fiction 
One of the most controversial aspects of the PCPT was the finding of increased 
prevalence of high-grade tumors among those taking finasteride. The authors of the 
PCPT suggested two possible explanations. First, finasteride may induce high-grade 
tumors by inhibiting intraprostatic conversion of testosterone to dihydrotestosterone 
(DHT). Decreased levels of intraprostatic DHT are analogous to men with low serum 
testosterone levels. Prostate cancers arising in these men have been shown to be of 
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higher Gleason grade and are associated with worse outcomes.95 Second, it is also 
biologically plausible that finasteride selects for high-grade tumors by inhibiting or 
treating low-grade tumors. At present, no evidence supports this hypothesis. 
In examining the ratio of excess high-grade tumors as broken down by year in the 
PCPT it can be seen that the largest discrepancy occurred in the first and second year of 
the study (see Figure 3).96 
Figure 3: Proportion of excess high-grade cancers in each year of the PCPT (adapted from 
Roehrborn, 2003) 
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In particular, to have 2.5 times as many high-grade cancers detected in the first year of 
the study violates one of the causal criteria of Hill: temporality.97 It is highly unlikely 
that finasteride could either induce or create a selective environment so rapidly to observe 
that many excess high-grade tumors. Similarly, if this were a case of induction, then the 
ratio should increase over time as more tumors have been exposed to the inducing factor. 
This violates another causal criterion of Hill: consistency. 
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Based on this observation, several theories have been put forth in attempt to 
explain how the false increase in high-grade cancers arose. One possibility is histological 
artifact. It has been shown that by reducing intraprostatic DHT, finasteride causes similar 
architectural changes as androgen deprivation therapy.98 Specifically finasteride has been 
shown to cause atrophy and involution, smaller nuclei and nucleoli, increased apoptosis, 
decreased vessel density and decreased cellular proliferation.99. 102 In the case of 
androgen deprivation therapy (ADT), a consensus panel has concluded that Gleason 
grading of tumors post-ADT is of no value. 103 No formal recommendation has been 
made for 5-alpha reductase inhibitors, however, two systematic reviews have 
recommended that chernoprevention trials using these agents should avoid using Gleason 
grade as a secondary end-point because of this grading bias. 98• 104 
A recent study examined 369 TRUS guided biopsy specimens in men with PSA 
<1 0 nglml that subsequently went to radical prostatectomy. They found that prostate 
volume, as determined by TRUS, was a significant predictor of finding a Gleason pattern 
4 or more in the biopsy specimen. However, prostate volume is not a significant 
predictor of high-grade disease in the RP specimen. Stated another way, the sensitivity of 
TRUS biopsy to identifY high-grade disease was highest (81 %) in glands <30.7 cm3, but 
decreased to 62.5% in glands greater than 53.4cm3 . 105 1bis disparity in sensitivity 
dependent on gland volume amounts to an overdetection bias and could explain why 
those on finasteride had a higher prevalence of high grade tumors: their prostates were, 
on average, 25% smaller in volume. 
In further support of this histological artifact, a post-hoc analysis of 159 of men in 
the PCPT diagnosed with a Gleason 8 or higher tumor that went on to RP was completed. 
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Though presented only in abstract form to date, it showed that those on finasteride had 
significantly fewer bilateral tumors (26.5% vs 44.3%, RRR 40.2; p=0.002).106 Until this 
publication appears in the peer-reviewed literature in its entirety it is difficult to comment 
on the validity of the results. They have obviously included incident cancers since the 
termination of the PCPT because at the study close date, only 143 such cancers had been 
identified. Regardless, if the finding holds, this further supports that the excess high-
grade tumors seen were histological artifact. 
Finally, additional analyses have been completed on over 500 radical 
prostatectomy specimens from participants in the PCPT. These were reviewed by a 
blinded uropathologist. It was found that there was no longer a significant difference in 
the proportion of Gleason 7-10 cancers between the two groups. 107 This finding has yet 
to reach even abstract form and so should be interpreted with caution. 
In summary, despite biological plausibility that finasteride induces or selects for 
high-grade cancers, further analysis of the PCPT data corroborated by other studies 
suggests that the excess high-grade cancers seen are a product of overdetection bias and 
histological artifact. 
Key Question #4: what costs are associated with using finasteride in every male patient 
within the defined population to prevent prostate cancer? 
Key Question #5: have studies modeled the potential benefits ofusingfinasteride to 
prevent prostate cancer? 
Key Question #6: what is the cost-effectiveness ofusingfinasteride to prevent prostate 
cancer? 
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In choosing the primary end-point of prostate cancer period prevalence, the PCPT 
limited its ability to address whether finasteride use reduces overall mortality. The PCPT 
also did not assess any cost or utility parameters associated with the observed outcomes. 
This information is necessary before recommending mass implementation of a prevention 
strategy. As identified through the systematic literature search, the PCPT has spawned 5 
studies that attempt to answer these questions through modelling. No other literature was 
found that can address key questions 4 through 6, thus these three questions are discussed 
together in this section. 
All five studies are of fair or good quality. However, each one uses the PCPT 
data to answer a slightly different question using different methods and reporting 
different outcomes. Thus, pooling of these data is not feasible. By way of summary they 
are presented in table 4. Data shown represent the net benefit of treating a group of men 
with finasteride for 7 to 10 years. The unit of analysis ranges from a single man to the 
entire U.S. population of men. Men considered are over the age of 55 and have not 
already received a diagnosis of prostate cancer when they begin finasteride treatment. 
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Table 4: Summary of studies modelling benefit-risk, survival and cost outcomes based on PCPT 
findings 
in arm 
needs to triple 
before PYS~O 
* = RP assume treatment with radical prostatectomy; WW assume treatment 
HG ~ higb-grade tumors (Gleason 7-10) 
most influential 
parameter 
If RR of high grade in 
0 =Refers to either a) over-detection of cancers in finasteride ann because of reduced gland size; orb) over 
detection of cancers in both arms because of end-of-study biopsy protocol 
The most simplistic of the studies was by Klein eta!., a subset of authors from the 
PCPT.108 They calculated an absolute benefit-risk ratio based on PCPT data. This ratio 
was the absolute reduction in prostate cancer risk over the absolute excess risk of high 
grade cancers (Gleason7-10) when treated with finasteride. This ratio was computed to 
be 4.6:1, meaning that for every 4.6 prostate cancer cases prevented, 1 excess high grade 
cancer is diagnosed. 
Altering the assumed percentage of excess high-grade cancers due to artifact 
between 10 to 50% yielded increased ratios as shown in Table 4. Similarly altering the 
number of cancers detected in the finasteride arm based on the assumption that the 
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smaller glands in finasteride treated patients led to sampling bias and over-detection 
revealed increased ratios ranging from 8.2:1 to 16.3:1. 
Such positive results would favor large scale implementation of finasteride. 
However, this study is only of fair quality and warrants caution. First, the ratios they 
presented are based on the prevalent cancers in PCPT, meaning those from both for-cause 
and end-of-study biopsies. Such cancers may not represent those that are commonly 
diagnosed in North America with current practice. Using data only from cancers detected 
by for-cause biopsies in the PCPT may be more representative. Doing so lowers the 
overall benefit-risk ratio to 1.9:1 and even in the most favorable setting of assumptions 
regarding grade artifact and overdetection, the ratio is only 8:1. 
Second, the relative value assigned to one cancer prevented and one excess high 
grade cancer is not discussed. As evident from their analysis, they are assuming that the 
relative value ofboth outcomes is equal, but this may not necessarily be true. A more in-
depth analysis would project the survival of the high grade cancers relative to the low 
grade cancers and compare this value to preventing predominantly lower grade cancers. 
Unger et a!., expanded on the idea of absolute benefit-risk ratios and estimated 
person-years saved by using finasteride as a chemopreventive agent. 109 Using SEER 
survival data for men with prostate cancer of differing grades and National Center for 
Health Statistics actuarial data for men without prostate cancer, the number of years of 
life saved by using finasteride was calculated. They calculated that 262,567 person-years 
would be saved if the entire U.S. population of men over age 55 were treated with 
finasteride for 10 years. Of note, according to their models, the excess high-grade tumors 
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in the finasteride ann would have to triple relative to those not taking finasteride before 
the survival benefits of finasteride were cancelled out. 
This study is of better quality than that of Klein et al. A particular strength is that 
they did not model cancer incidence based on PCPT period prevalence. Rather they used 
SEER incidence rates, which are much lower and more in keeping with current 
population rates. However, one weakness is they did not attach a quality value to these 
life-years saved nor a cost. 
Two studies, one by Lotan et al., and the other by Grover et al., modelled similar 
outcomes: 15-year cancer-specific survival and overall survival.110• 111 Grover et al., used 
a validated Markov model, while Lotan et al., developed their own decision analysis 
model. The Lotan et al., study was unique in that they stratified their projected outcomes 
based on whether men were treated with watchful waiting or radical prostatectomy. 
Based on recent data from an RCT from Scandinavia showing an overall survival benefit 
in men with localized prostate cancer treated with radical prostatectomy over watchful 
waiting, this stratification seems appropriate. 113 
Lotan et al., showed men with the same inclusion criteria as the PCPT, given 
finasteride for 15 years and treated with radical prostatectomy if they had cancer were 
estimated to have 1. 7 months longer cancer specific survival as compared to if they had 
not been treated with finasteride. This survival advantage dropped to less than 1 month 
in men treated with watchful waiting. Grover et a!., while not stratifYing based ultimate 
treatment, found a similar 1. 7 month overall survival advantage in men treated with 
finasteride for 15 years. Comparing this to other primary prevention modalities, 
childhood vaccines, such as measles, rubella and pertussis increase life expectancy by 
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about 0.1 month each.114 Screening for cervical cancer will increase a woman's life 
expectancy by 3 months115 and tamoxifen in breast cancer prevention will increase life 
span by 0.9 to 2.3 months depending on the age at which it is initiated.116 
In assuming that the grade difference was artifactual, a near doubling of cancer-
specific and overall survival was noted. By changing model probabilities based on for-
cause biopsy data only (see 8b in Table 4) where the overall incidence of prostate cancer 
was markedly less, survival estimates drop considerably. So much so that in younger 
men, those on finasteride have a decrease in cancer-specific survival by 0.2 months. This 
point was illustrated in both studies that as the incidence of prostate cancer in the 
population being modelled increases, the benefit of finasteride increases. From this 
finding, it has been postulated that if we can identifY a subgroup of men who are at higher 
risk for prostate cancer, that finasteride may be more beneficial. The REDUCE trial, 
mentioned earlier, will be able to address this issue, as the source and study population 
are inherently higher risk. To be eligible for the trial, men had to have been biopsied for-
cause at least once. 117 
Both the Lotan et a!., and Grover et a!., studies were of good quality. However, 
the survival benefits attributed to finasteride should be cautioned as the use of PCPT data 
to model cancer incidence rates may artificially inflate the benefits. Furthermore, they 
did not attempt to assign relative values, either economical or psychological, to cancers 
prevented, low grade cancers or high grade cancers. 
The most complex of the 5 studies, by Zeliadt et a!., modelled cost per life year 
saved and cost per quality adjusted life year (QAL Y) and addressed several weaknesses 
identified in the four prior studies. 112 They used SEER data to model the incidence of 
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prostate cancer, high grade disease and the outcomes of those with cancer in the general 
population. Cost of finasteride was estimated based on men starting at age 55 and 
continuing finasteride daily until age 85 or their first diagnosis of prostate cancer. 
Unique to this study, they also modelled the benefits of finasteride relative to BPH 
symptoms and surgery. In assigning utility to each health state, they accounted for the 
psychological burdens and quality oflife changes. 
It was estimated that their base cohort of 1000 men treated with finasteride would 
gain 6 life-years survival and 46 QAL Y s relative to men not taking finasteride. Each life 
year came at a cost of $1,660,000 while each QAL Y cost $200,000. Only men living 
beyond age 80 derived any benefit from preventing low grade tumors. Assuming the 
excess high grade tumors were due to artifact increases the life-years and QAL Y s gained 
and reduces the cost for each year respectively (see Table 4). In a sensitivity analysis, 
grade proved to be the most influential parameter. It was found that the true relative risk 
of high grade tumors in the finasteride arm relative to the placebo arm would have to be 
1.8 before the benefits of finasteride were eliminated. 
Even using the most favorable assumptions, Zeliadt eta!., concluded that the cost 
per QAL Y is substantially higher than the $100,000 willingess-to-pay threshold per 
QAL Y that is often used as a benchmark. 118 It was estimated that the cost offinasteride 
must be reduced by 50% from its current average wholesale price and finasteride must 
prevent high-grade disease equally well as low-grade disease before the cost-benefit will 
be justifiable. 
In summary, five studies have attempted to use the PCPT data and answer 
practical questions regarding harms relative to benefits, survival, and costs. With the 
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variance introduced by unknown grade artifact and over-detection biases, it is difficult to 
precisely estimate the benefit relative to the risk. However, it appears, those at highest 
risk of prostate cancer and those most likely to live beyond 80 will benefit the most from 
finasteride. Even if it is proven that the excess high-grade tumors seen are explained by 
artifact and that substantial over-detection occurred in the finasteride arm, the benefits of 
finasteride are modest. At present, the costs to achieve these benefits appear steep. 
Summary of systematic review 
Overall, there is good quality evidence to show that finasteride is efficacious in 
reducing the period prevalence of prostate cancer. While side-effects are minimal, the 
potential increased risk in high-grade tumors is worrisome. Though not conclusive at 
present, evidence is suggestive that the excess high-grade tumors observed in the PCPT 
may be fallacious. There is insufficient evidence to assess the influence of finasteride on 
the performance of current screening modalities. There is good quality evidence the cost-
effectiveness of treating men over the age of 55 with finasteride to prevent prostate 
cancer is modest at best. Thus, presently, there is insufficient evidence to recommend 
finasteride use in every man of average risk for prostate cancer. 
If the grade issue is cleared definitively or a subset of higher risk patients is 
identified in which finasteride is most effective, then in future, there may be sufficient 
ground to recommend its use. 
Guideline consensus 
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To compare the findings of my systematic review with current guideline 
recommendations, a guideline search was conducted using the National Guidelines 
Clearing House and the search engine Google™. Only one guideline was identified that 
dealt directly or indirectly with the issue of finasteride as a prostate cancer 
chemopreventive agent. The National Cancer Institute produced a guideline which 
assessed whether finasteride can reduce the mortality attributable to prostate cancer. 
They concluded that, "based on solid evidence, chemoprevention with finasteride reduces 
the incidence of prostate cancer, but the evidence is insufficient to determine whether 
chemoprevention with finasteride reduces mortality from prostate cancer." 119 This is in 
line with the results of my systematic review. 
Dissemination of the evidence 
Dissemination is defined as, "a scattering or spreading abroad, as of ideas, beliefs, 
etc.; diffusion for propagation and permanence.'ol20 This term has been applied to 
describe how evidenced-based medicine propagates from scientific discovery to regular 
practice. As identified in the systematic review above, evidence for a chemopreventive 
agent for prostate cancer was scarce before the publication of the PCPT. Thus, the 
National Cancer Institute (NCI), which funded the PCPT, had the task of beginning the 
process by disseminating the results of the PCPT to the public and physicians. They 
outlined 5 main messages to communicate with these results: 1) to accurately convey the 
scientific excitement that prostate cancer risk was shown to be reduced with a drug 
intervention; 2) to appropriately explain the side effects, both well-documented and 
potential; 3) to discuss the risk-benefit trade-off associated with any drug intervention; 
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and 4) to impress upon the public that prevention interventions such as finasteride are not 
acute medical decisions but should be made after careful consideration.121 From these 
goals, it can be seen that the NCI was careful not to appear clearly in favor or against 
using finasteride as a chemopreventive agent for prostate cancer. Rather, they focussed 
on ensuring that accurate information regarding the trial was delivered, while letting the 
individual physicians and thought leaders sort through the uncertainty. Releasing this 
information was complicated by the fact that millions of men were already taking 
finasteride for treatment ofBPH or, at a lower dose, for male pattern baldness. Thus, the 
effects on overall use of finasteride, regardless of indication are difficult to predict. 
It may be possible to estimate the rate and magnitude of influence the PCPT 
results would have on prescribing patterns by examining other large impact RCTs. The 
Women's Health Initiative (WHI) trial showed that overall risks exceeded benefits in 
using combined estrogen and progestin in postmenopausal women. 122 After its 
publication in July 2002, prescriptions for hormone replacement therapy dropped 
dramatically. In Ontario, Canada, prevalence of hormone replacement therapy (HRT) 
prescriptions was 32% lower in the last quarter of 2002 in comparison to the first quarter 
of2002 (Figure 4). 123 
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Figure 4: Prevalence and incidence of use of HRT in elderly women 
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The rapid decline may be, in part, due to tbe concomitant decline in promotional 
spending by pharmaceutical companies regarding hormone replacement therapy. 124 
Similarly, a 400% increase in prescriptions for ramipril in Ontario was seen within a year 
of publication of the Heart Outcomes Prevention Evaluation (HOPE) which showed 
ramipril is effective in secondary prevention of cardiovascular disease (Figure 5). 125• 126 
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Figure 5: Numbers of new prescriptions for angiotensin-converting-enzyme 
inhibitors filled by elderly (aged 65 and over) Ontario residents. 
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Similar trends have been observed in prescriptions of diuretics and angiotensin 
converting enzyme inhibitors after the publication of the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).127 The ALLHAT trial 
also affected prescriptions for doxazosin. The doxazosin arm of ALLHA T was 
terminated early because of a 2-fold increased risk of congestive heart failure attributed 
to the alpha-blocker. Before publication of ALLHAT, use of alpha-blockers was 
gradually increasing. Within 2 years of this publication, physician-reported alpha-
blocker prescribing decreased by 54%. 124 This reduction was not explained by changes 
in pharmaceutical promotion, cost of doxazosin or introduction of generic drugs. Finally, 
statins have also seen similar fluctuations after the publication of major RCTs. 128 
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Using an example more specific to prostate cancer, in Aprill991, Catalona eta!., 
published an article in the New England Journal of Medicine endorsing the use of 
prostate cancer screening with a PSA cut-off of 4.0 ngim1.129 A large health maintenance 
organization in Washington reported a 3-fold increase in the ordering ofPSA tests 
immediately after the publication of this paper. 130 No doubt as a result of the rapid 
increase in PSA testing, in the month after the publication of the Catalona eta!., article, 
prostate cancer diagnoses arose by 87% in men in the Health Professionals Follow-Up 
study(Figure 6). 131 This rapid dissemination is somewhat surprising given the quality of 
the original Catalona et a!., article. The article was very controversial in that they did not 
have an unscreened asymptomatic control group for comparison. 
Figure 6: Rate of prostate cancer diagnoses over time in the Health Professionals 
Follow-Up Study. 
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It is not known to what degree finasteride use has increased or decreased after the 
publication of the PCPT. It is also difficult to estimate given that no studies have 
examined the determinants of dissemination of primary prevention innovations relative to 
cancer. Pentz reviewed the elements of diffusion of drug abuse prevention research and 
categorized 4 stages of diffusion: adoption of a new program, implementation of the new 
program with fidelity, dissemination of the program within a system and sustainability of 
the program once disseminated. 132 Pentz further summarized barriers to adoption, 
implementation and dissemination phases. Among the common themes was inadequate 
funding or infrastructure, lack of program teaching materials, lack of positive 
communication or lack of network structures to diffuse positive commnnication. 
Comparing such descriptions to the use of finasteride for prostate cancer 
chemoprevention is difficult. After the results of the PCPT, no formal program was 
established to disseminate the innovation. Infrastructure has been established to spread 
the results of the PCPT but, similar to the neutral message from the NCI, teaching 
materials and communication networks do not promote the use of finasteride as a 
chemopreventive agent. 
Donald Berwick identified three clusters of influence that correlate with the rate 
of diffusion of innovations: perceptions of the innovation, characteristics of the people 
who adopt the innovation (or fail to do so), and contextual factors involving 
communication, incentives, leadership and management.1 
It has been shown that perceptions of a new innovation account for up to 90% of 
the variance in the rate of spread of the innovation.133 Within these perceptions, the most 
powerful is the perceived benefit of adopting the new innovation relative to harm. In a 
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situation of uncertainty regarding this perceived risk-benefit ratio, the more knowledge 
individuals can gain about the expected consequences of the innovation, the more likely 
they are to adopt it. In the case of finasteride as a chemopreventive agent, it is likely that 
perceptions are mixed and uncertainty looms. Despite the few studies modelling results 
based on the PCPT data, little new data has emerged to assuage the perception of 
uncertainty. Thus, it is largely unknown how finasteride is perceived in the United 
States. In addition to the perceived risk-benefit, perceptions of new innovations are 
determined by how compatible the new innovation is with values and beliefs of the 
physicians as well as the complexity of the innovations. Generally, physicians are loath 
to subject healthy men to the potential adverse effects of drugs unnecessarily. As such, 
finasteride may not be compatible with most physicians' values and beliefs. However, 
finasteride chemoprevention is a relatively simple concept at face value, one pill per day 
for every man. This simplicity would be expected to facilitate dissemination. 
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Research Project: 
Use and knowledge oflmasteride in the primary prevention of prostate cancer-
Trends in prescriptions and a survey of VA primary care physicians and urologists 
Rationale 
Given the burden of suffering attributable to prostate cancer, the potential impact 
a chemopreventive agent like finasteride could have is considerable. As identified by the 
systematic review however, the issue of the benefits relative to harms of using finasteride 
as a chemopreventive agent is not clear. Moreover, how physicians respond to this 
uncertainty is not known. 
To better understand the dissemination of finasteride in the primary prevention of 
prostate cancer, the proposed project has two elements. First, we seek to quantifY the 
change in finasteride use over time and whether this use changed with the publication of 
the PCPT. Second, we seek to understand the key elements of dissemination outlined by 
Berwick, specifically the perceptions, characteristics and contextual factors of those 
physicians who are in a position to utilize finasteride. 
A better understanding of the current state of dissemination of finasteride 
chemoprevention information, specifically finasteride use and knowledge, could allow 
directed educational interventions and guide future research to target areas of physician 
uncertainty. 
PROCEDURES/METHODS 
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Design 
This study is divided into two parts. Part A involves the collecting and analyzing 
prescription data for finasteride and alpha-blockers using the VA phannacy benefits 
management (PBM) database system. Part B involves surveying VA primary care 
physicians and urologists regarding their use, knowledge and perceptions offinasteride as 
a chemopreventive agent. 
Study population 
The source population includes VA primary care physicians and urologists in the 
United States. Eligibility criteria include physicians registered as a full-time equivalent 
(FTE) at a VA institution in the fields of urology, family or general practice, general 
internal medicine, or geriatrics. Resident physicians, physician assistants and nurse 
practitioners will be excluded. A list of all such eligible physicians will be generated by 
the from the Personnel and Accounting Integrate Data (PAID) payroll system by the 
Veterans Evidence-Based Research Dissemination Implementation Center (VERDICT). 
All FTE urologists (325) will be invited and a random sample of 1000 primary care 
physicians from the 4557 FTE PCPs will be selected. Those chosen will be sent email 
invitations. Sampling will not be stratified for geographic area, but our hope is that our 
study population will represent practice patterns across the United States. Thus, the final 
study population will be comprised of those physicians who meet the eligibility criteria, 
do not meet the exclusion criteria, have the ability to receive email, and respond to the 
survey invitation. 
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Sample size 
For an estimated target population size of 5,000 VA primary care physicians and 
urologists, with a 95% confidence level, a 4% confidence interval (or margin of error) 
and a 50% prevalence for each response, the required sample size is 536. This was 
computed using the formula: 134 Ns = (Nvi (vi CI-p) 
(Np-1) (BIC/ + (p)(l-p) 
Where N s = the number of completed surveys needed for the desired level of 
precision; Np =size of the source population; p =proportion of the population expected 
to choose one of the two response categories (estimated conservatively at 0.50); B= 
acceptable amount of sampling error (set to 0.04); C = z-statistic associated with 95% 
confidence level (1.96). The confidence interval or margin of error refers to how 
accurately the proportion revealed from the survey population represents the actual 
proportion in the source population. For example, if 68.5% of respondents reported they 
use finasteride as a chemopreventive agent, and the confidence interval was set a priori to 
4%, then the true proportion lies within 68.5 ± 4%. The confidence level refers to the 
precision of the survey sample. That is, the probability that, if the population were 
sampled and surveyed in a similar fashion repeatedly, the resulting values would fall 
within the specified margin of error. Using the same example, if68.5% of respondents 
reported they use finasteride, and the confidence interval was set to 4% and the 
confidence level was set to 95%, then if the survey were repeated I 00 times, 95/100 
times the observed proportion would fall within 4% of 68.5%. 
We estimate a 45% response rate, thus 1191 email invitations will be sent. 
Enrolment is accomplished by respondents accessing the online survey and completing 
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the survey. Though IRB approval is still pending, we have requested a waiver of formal 
informed consent. Thus, no formal signed informed consent process will take place. 
Consent is implied when the physician completes the online survey. 
Variables/Interventions 
Part A: 
The primary data to be collected for Part A are all prescriptions for finasteride 
written between October I, 1998 and December 31, 2005. Additionally all prescriptions 
for alpha-blockers will similarly be obtained. Capturing alpha-blocker prescription 
trends will serve as a pseudo-control for finasteride prescriptions. MTOPS confirmed the 
combination of finasteride and alpha-blockers was superior to treatment with either 
finasteride or alpha-blockers alone. This trial was published shortly after PCPT in 2003. 
Thus, rises in finasteride prescriptions after 2003 may not be attributable solely to use in 
a chemopreventive role, rather in combination treatment for BPH. By ascertaining rises 
in alpha-blocker therapy, it may be possible to determine what proportion of rise in 
finasteride prescriptions is attributable to use in BPH. October I, 1998 is the date of first 
entry for the PBM database. 
Part B: 
For Part B survey domain variables include: current practice patterns regarding 
diagnosis and treatment of BPH, frequency and indication for finasteride use, what the 
physician discusses with the patient, knowledge of issues surrounding finasteride use in 
both benign prostatic hyperplasia and for prevention of prostate cancer, and where the 
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physician finds such information (guidelines, journals). The survey was designed de 
novo and is not based on prior surveys. After careful critique from the study team, the 
survey was administered to 15 physicians (approximately 50% primary care providers 
and 50% urologists). Final changes were made to the survey and the final survey is 
attached as Appendix 2. The survey tool Zoomerang™ will be used to conduct the web 
survey. 
Data Collection: 
For Part A, data from the PBM database will be queried through the Department 
ofPharmacoepidemiologic Outcomes Research at the VA. This de-identified data will be 
downloaded to the VA National Center for Health Promotion and Disease Prevention and 
stored there. For Part B, those selected to be invited will receive an email inviting them 
to participate in the online survey. The invitation email is attached as Appendix 3. The 
email will include a link to a secured website provided by Zoomerang™ should they 
agree to participate. Zoomerang will collect all survey data in real-time as the survey is 
being completed. Upon completion, the results will initially be mapped to the email 
address of the person completing the survey. This is only for the purpose of eliminating 
that person's name from the list of people who have not completed the survey. When the 
survey is terminated, the results will be downloaded en bloc and all identifYing data will 
be removed by one of the study personell. Results will be downloaded into an Excel 
spreadsheet at the VA National Center for Health Promotion and Disease Prevention. 
Once downloaded, all data (Part A and Part B) will be stored in de-identifed form and 
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will not be shared or made accessible to anyone outside of the Center. Analysis will done 
using the statistical software package Stata™(Version 9.0). 
Data analysis and sample results 
Part A - PBM prescription data: 
Prescription data for finasteride and alpha blockers will be analyzed. First, the 
total number of prescriptions written for finasteride and alpha-blockers will be plotted 
over time on a month-by-month basis. Example data are displayed in Figure 7 below. 
Alpha-blocker data will be subclassified into selective and non-selective. The specific 
time point of interest is July 2003, when the PCPT was published and December 2003, 
when MTOPS was published. It is hypothesized that finasteride prescriptions will 
significantly increase thereafter. A two-sided Cox and Stuart test for trend will be used to 
determine if there is a statistically significant trend in finasteride or alpha-blocker 
prescriptions. Then exponential smoothing models will be applied to model finasteride 
and alpha-blocker prescriptions, and finally, using multivariate time-series techniques, 
confounding variables, such as geographic location and physician (PCP vs urologist), will 
be controlled for. Mean finasteride prescriptions from January 2004 to 2006 will be 
compared with mean finasteride prescriptions from Oct 1998 to June 2003 using at-test. 
A similar analysis will be done with all alpha-blockers, and then stratified based on 
selective and non-selective alpha-blockers. 
65 
Figure 7: New fmasteride and alpha-blocker prescriptions over time 
---
. . (. 
Then, the prescription data will be classified according to primary care physician 
or urologist prescription. Within these categories, prescriptions will be plotted over time. 
Sample data are shown in Figure 8 below. These data will be analyzed using longitudinal 
models to detect significant differences between primary care physicians and urologists 
within each category of pharmaceutical. 
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Figure 8: Prescriptions for fmasteride and alpha-blockers written by primary care 
physicians and urologists over time 
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Part B- Physician Survey: 
Within each domain of the survey, all closed-ended questions will produce 
categorical data and will be analyzed with the chi-squared statistic. Comparisons will be 
made between urologists and other primary care physicians, academic versus community 
physicians, physicians serving different proportions of African American patients and age 
of physicians. Table 5 illustrates a sample categorical table and chi-squared statistic 
generated from the survey results. 
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Table 5: Assessment of knowledge: "What effect does lmasteride have on PSA 
LEVELS? (Choose 1)" n=583 
50 3 53 
P=0.007- Chi-squared test 
Bias and Limitations: 
In Part A, with the PBM system nearly all outpatient prescriptions written by VA 
physicians will be registered in the PBM database. Given the low copayments for 
prescriptions in VA pharmacies, there is strong incentive for patients to obtain all their 
medications from VA pharmacies. Nonetheless, it is possible for patients to receive 
finasteride from pharmacies outside the VHA. Such activity would cause an 
underestimate of the total number of prescriptions written, but would be unlikely to 
influence the relative trend in prescriptions over time. 
As mentioned above, changes in finasteride use may represent use in treating 
BPH or use in prostate cancer chemoprevention. Given that finasteride is not FDA 
approved to use in a chemopreventive setting and there is no ICD-9 code to identifY a 
person who is being treated for chemoprevention, it is impossible to capture this data on 
this scale. However, we have attempted to minimize this bias by ascertaining alpha-
blocker prescriptions. It may be possible to estimate the proportion of the increase in use 
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of finasteride due to BPH treatment by measuring the increase in alpha-blockers at the 
same points in time. 
However, alpha-blockers, particularly the non-selective ones, may be used for 
treating hypertension as well as BPH. This may cause an overestimate of the use of 
alpha-blockers. This bias is susceptible to changes over time, as publication of evidence 
pertaining to alpha-blockers in treatment of hypertension has been shown to change 
prescribing habits.135 
In Part B, there is potential for selection bias given that those physicians most 
likely to respond may over-represent physicians who are up to date on the literature. 
Since it is an online survey, respondents may also over-represent younger, more 
computer savvy physicians who work at larger academic centers with readily available 
internet access. As such, one of the largest potential limitations of this study pertains to 
response rate. Physician enrolment in survey studies is highly variable ranging from 45% 
to 74%.136"139 For our sample size calculation above, we used the most conservative 
response rate estimate of 45% to minimize the influence of poor response rate on our 
results. 
Overall Conclusions 
The burden of suffering attributable to prostate cancer is large. However, much 
of this burden is not caused by prostate cancer deaths, but rather by the psychological and 
physical burdens of receiving a diagnosis and undergoing treatment. Thus, preventing 
prostate cancer appears the best strategy to reduce this burden. With insufficient 
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evidence supporting screening, attention has turned to chemoprevention. Finasteride has 
shown the most promise and has the best quality of evidence supporting it. 
It is clear that finasteride reduces the period prevalence of prostate cancer. 
However, it is not clear that the tumors prevented would have ultimately been diagnosed 
or warranted treatment. It is also not clear whether finasteride may increase the risk of 
high grade tumors. With the intimidating costs of treating every man of average risk with 
finasteride for life, the cost-effectiveness is modest at best. Thus, the decision to place 
men on finasteride is marred with uncertainty. 
The uncertainty surrounding use of fmasteride to prevent prostate cancer is 
unlikely to be resolved for several years. Yet finasteride is still available for long-term 
use in treating BPH, and may well be used by some physicians to prevent prostate cancer 
despite the controversy. Given the potential impact finasteride has on prostate cancer 
incidence, aggressiveness and PSA levels, the insight gained regarding the current use of 
finasteride is important. Discovering that many men are currently taking finasteride, but 
that physicians are not well informed regarding the influence of finasteride on parameters 
such as PSA, prostate volume and the potential increased risk of high grade tumors may 
indicate a need for directed educational interventions for both physicians and patients. 
Understanding physician perceptions of the current evidence for finasteride as a 
chemopreventive agent will help guide future research and tailor guidelines to address the 
areas of greatest concern or uncertainty. I hope to gain insight into the different levels of 
knowledge and perception between PCPs and urologists. Such information could guide 
future recommendations for when PCPs should refer a patient to a urologist. 
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Until new evidence is presented clearing the picture for finasteride or identifying 
a new promising chemopreventive agent, men are best served through a better 
understanding ofhow current evidence is interpreted and assimilated. 
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Appendix 
Table Short-forms: 
Bx- biopsy 
PEP- primary end-point 
SEP-
CaP -prostate cancer 
BCR -biochemical recurrence 
PIN- prostate intraepithelial neoplasia 
LUTS- lower urinary tract symptoms 
AUA SxS- AUA symptom score 
Qmax- maximum urinary flow rate (ml/sec) 
SWOG- Southwestern Oncology Group 
PFS - Progression free survival 
CSS -Cancer-specific survival 
MFS -metastasis-free survival 
PSAD- PSA density 
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Key Question #1- Abstraction Table 
from 
!database of CaP 
!
treatment score 0.4 for 
control, 0.5 finasteride 
1.6 forLHRH 
users: 
/high-grade tumors 
IJ~~AlU~ do not, but warrant further 
a consecutive 
-BCR: 
!underpowered, no 
]control for 
ity study. 
!Conclusion, even if true, 
NOT answer the 
question of whether 
fmasteride may artifactually 
increase the grade 
659 no Cap Use categorized Multivariate: finasteride) Not avg Risk population 
as user if: -NSAIDS: OR 0.84 High risk: Hospital 
>15/month, (0.66-1.07) referral pop: not 
>!/month,< -Finast: 0.58 (0.37- avg risk popn 
I/ month 0.92) No adjustments for 
Non user if never PSA in finest rx 
Innappropriate 
classification of 
exposure 
Quality -poor 
Andriole et al; 3 RCTs pooled Dutast 0.5 Cum Incid by CI at 24.4 months Cumulative Incidence At 27 months, open Cancer status before trial not 
2004 4325 men with Vs non-protocol 1.1 % dutast lower in dutast group label may have lmown; indications for 
Pooled 3 RCTs BPH Placebo mandated biopsy 1.9% placebo lead to increased biopsy or biopsy cores not 
PSA 1.5- 10 X24 P=0.025 biopsies in placebo specified. 
months HR 0.61 (0.37-1.02) group Path specimens not 
Then open CI at 27 months centralized 
label ext 1.2% dutast Quality- poor 
2.5% placebo Fatal flaws 
p=0.002 introducing bias 
HR 0.49 (0.31-0.77) Do not have a good 
Path data only available sense of these men. 
in 27 subjects (no sig Inappropriate 
dit) pooling 
Cote et a!; 1998 52 men Finest Biopsied at 12 PEP - % change in uprovides little Not clear who With only 9 cancers 
RCT 11 Several 5mg (27) months: hyperplastic epithelium evidence that these men are detected, high chance of 
institutions!!?? Placebo PEP:% -8.3 finast vs -2.9 finasteride is an Unclear source spurious findings 
PSA>4.0 (25) hyperplastic placebo; p=O.ll effective popn 
previous neg Bx X !2 tissue SEP- chemotherapeutic Likely many of these men 
months SEP: Finast 30% cancer vs agent" in high risk Very Short already had 
Cancer+/- 4% placebo (p=0.025) men cancer ... therefore can1t 
PIN+/- Quality - Poor conclude that finast does not 
Pathologist prevent cancer 
blinded Finast shrinks gland size: 
detection bias 
Operational? Control group 
issue 
Guess et al; 1997 125,000 men from Serum marker Quality: good Not directly applicable to 
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Nested case- Kaiser Permanente levels: Asking the wrong KQ#l 
control 1964-1971 Total T, question 
I 06 cases selected FreeT 
Controls: matched Andosterone 
age, date of serum 
and clinic location 
Stoner eta!; 1994 1645 age 40-83 Finast I or Unspecified 12 cases of Cap during Unable to discern Again, CaP likely present 
Pooled results 2 BPH 5mg biopsy criteria 12 month study differences before the case began 
RCT's PSA >40: excluded Vs DRE and PSA at ( 4 placebo, 3 on lmg, 5 between groups at 
"North American N. America: Placebo 6,9, 12,18,24 on 5mg) baseline 
Study" 25 US, 5 Canadian 12 months months 20 cases of CaP in the Follow-up too short 
11 International centers total open extension 
Study" International: 
45 centers in 17 
countries 
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Key Question #2 -Abstraction Table 
ejaculate, erectile 
l
<lystxn, loss libido, ~Concerns regarding 
gyuecomastia: all more high-grade 
fmast (p<O.OOl) 
!frequency, retention, 
, prostatitis, UTI: 
less in finast 
. SEPs reduced as 
(see table in paper) 
finasteride (see 
4): 
deer libido, 
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documentation of side-
and harms. 
applicable to the 
!population of interest. 
of 
!
side-effects and harms. 
Though no cancer outcomes 
!Population in this study 
slightly different since 
with known BPH 
serum PSA still 
Adverse events -27% dlc'd fmast Rx 
18% d/c'd combo 
Breast Ca: 4 pts on 
finast; 0 on dox or plac 
Lowe eta!; 2003 1657 men from Finast Monitored q6mo 6 year data only for 487 Finasteride: durable Quality- fair Results in agreement with 
Pooled 6 year Phase II 5mg Prostate vol Finast men; 238 improvement in Only 50% of better quality studies. 
data from patients N.America and Qmax placebo men LUTS; prevealence original Doctor reported vs patient 
enrolled in BPH international trials Safety eva! Adverse events: see of adverse events randomized cohort reported 
RCT's After I yr double Non -validated table II in paper: does not increase included; not clear Instruments not standardized 
blind placebo instruments Finast had higher rates over time. how this sub-cohort 
controlled: asked of deer libidio, ejac, compares to one 
to participate in 5 impotence, breast another (?selection 
yr open extension complaints. bias: motivated 
on 5mg Finast Rates declined with patients) 
ORE: enlarged time. 6yr rates were -caution declining 
prostate lower than I yr placebo. rates with time: as 
Symptoms of Attrition large people drop out 
obstructive due to adverse 
uropathy events, people left 
Max flow <15 eels in study less likely 
to have side-effects 
McConnell et al; 3040 Finast Evaluated q4mon See table 3 Treatment with finast Quality- good Results in agreement with 
1998 Moderate to severe Smg Sx and Side Fx F inasteride treated arm for 4 years reduces Validated more recent studies. 
"PLESS 11 LUTS (using a Placebo using previously [had more deer libido, symptoms and instruments used Still doctor reported 
RCT "validated11 X4yrs validated impotence, deer prostate volume, symptoms but no bias 
symptom score but instrumen ejaculate, breast increases urinary between groups. 
not AUA or IPSS) Qmax enlargement, breast flow rate, reduces 
Qmax <15 PSA tenderness, rash probability of surgery 
ORE: enlarged ORE (p<0.05) andAUR. 
Exc: any The sexual symptoms More sexual side-
antiandrogen rx, hx lessened with longer effects in finasteride: 
of prostatitis, treatment lessen with time 
prostate or bladder Prostate cancer: 5% in 
cancer or surgery, each group. 
PSA <10 
Gormley et al; 25 US centers 297: Evaluated See table 4 in pape.r_for 5mg finasteride Quality ~fair _ Results in agreement with 
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1992 5 Canada centers Finast qmonth adverse events decrease obstructive Short follow-up more recent studies with 
RCTDouble 895 men 5mg Prostate volume F inast had higher rates symptoms and Instruments not longer follow-up 
blind, placebo Age40-83 298: Symptoms of: decreased libido, increases flow: but standardized 
controlled Sx ofobst finast lmg Side-effects ejaculatory disorder slightly increasd risk Doctor reported vs 
DRE: enlarged 300: (p<0.05) of sexual dysfunction patient reported 
prostate placebo Had NS higher rates of 
Qmax<l5 mVs 12 months abdo pain, flautulence, 
breast pain, dysuria, 
impotence, orgasmic 
------
... 
dysfunction, 
--
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Key Question #3- Abstraction Table 
!Interim Biopsies: 
I with cancer I increase 3 %/yr noncase, 
cases, 11 %/yr forlincrease 
(p<O,OOI) 
x High-grade 
!Placebo ann: HG cases !apparently 
PSA increase of 
annually vs LG 
ann: 
I
Noncance: PSA -5%/yr 
Cancer: PSA + 15% /yr !comparable 
5%vs 7% 
of 
l
fmasteride Rx 23,6 
!Predictive ability months 
yr estimate PFS 85% 
86% 
follow-up only 
months 
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compromise 
assigmnent of 
gleason grade for 
prediction tools !Outcome not 
Gleason grade 
remains an important 
prognostic predictor !conclusion 
finasteride in terms of 
velocity, but not absolute 
nnmber, Must multiply by 
this study useless 
PFS 
Kaplan et al; 3 8 men: baseline 5 mg fmas PSA measured 6 Mean baseline PSA Response to Quality - fair Outcome measured does not 
2002 serum PSA>4 od and 12 months 6.32 finasteride challenge No control group address key question 
Uncontrolled trial norma!DRE after Mean volume 37.3 cm3 among those with Small N specifically: further example 
>2 previous Repeat Bx at I yr lyrpsa: 3.73 (-41%) prior negative biopsy No a priori though of what finasteride 
negative biopsies Changes in Vol, lyr vol: 30.4 (-18.5%) could be prognostic definition of cut- does to PSA and Vol even 
PSA measured 29%CaP+: points for PSA after I year 
PSA 7.3-5.2 (-28.8%) decrease -men in this study are high-
Vol37.3-32.3 (-13.4%) risk: not applicable to our 
PSA decrease: popn of interest 
>50%: 0% cancers 
33-50%: 32% cancers 
<33%: 56% cancers 
Yang et a!; 1999 53 cases: (35 none Blinded path No significant Finasteide does not Quality - fair 2ndary data analysis from 
2ndary data finasteride, 18 review looking histological changes alter histological Only one PLESS 
analysis: PLESS placebo) for several were noted with appearance of cancer pathologist opinion 
50 control: (25 pathological finasteride 
finast, 25 placebo) characteristics 
Andriole et al; 3040 men age 4-78 Placebo PSAq4-8 21% had biosy Men tx with finast: Quality- Good Directly addresses the key 
1998 PSA <10 (1516) months 6.6% had turp Multiplying PSA by No selection bias question(best paper so far on 
RCT-PLESS No hx ofCa Finast(152 DRE annually CaP 4. 7% fmast vs 2 and using normal b/c PLESS this) 
2ndary analysis If pre-study PSA 4) I" 4 yrs: 5.1% placebo ranges for untreated selection was Essentially validated current 
>4: negative X 4 years investigators Elevated PSA prompted men preserves the clean. Magnitude practice of multiplying by 2 
prestudy bx req'd unaware of Dx in 35% offinast usefulness of PSA for of these results 
actual PSA cases and 34% placebo CaP detection enough not to 
values. Just told AUCPSA: question whether 
if it met Finast 0.84 Bias would drive 
threshold (>0.5 Placebo 0.79 p~0.07 result below 
change/yr on Use of cut off ofPSA significance 
finast, >2/yr on 2.0 for fmast and 4.0 for 
placebo) placebo: similar 
After 4 years: sensitivity 66% vs 70%, 
told adjusted but higher specificity 
values like PCPT (82% vs 74%) 
~~l_!l!:K~! __ ~l; 72 with BPH from Finast PSA doenat Similar results between Finasteride decreases Quality - Fair But does it cause 
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1997 IBPH study 5mgvs days 1,2,7,14 and 2 studies PSAby50% Mixing of overdetection of indolent 
Pooled data from 77 with BPH and placebo months 1,2,3,4,6 PSA nadir around 12 Doubling ofPSA in distinctly different cancers: we cannot tell this 
2RCTS CaP from X6 Blinded to PSA weeks oftx finast groups does not patient populations without a study examining 
BPH/CaP study months Placed into strata At 3 months: PSA drop mask detection (Cancer and not) is mortality 
50 of 77 had TURP based on baseline 56% in BPH, 46% in not appropriate. 
already which led PSA BPH and CaP for low However, short 
toDx PEP: % change strata vs 44% and 53% follow-up and 
8 US centers inPSAfrom for hlghstrata endpoint choosen: 
14 european [baseline may be able to get 
centers PSA doubled for away with it. 
age 44-80 finast after 3 
PSA 1-10 months tx 
Gormley et al; 895 men Finast Volume:MRI Analysis combined 1 PSAD may provide Quality - fair Adjunctive evidence 
1994 30 centeres in lmg (to PSA: central lab and 5mg finasteride additional Not clear who showing that PSAD may 
2ndary analysis N.America 50%) and -at baseline 3, 6, Finast increased the reassurance without these men are, nor have fair Sn and Sp 
of 12 month RCT age 40-83 5mg (to 12 months PPV ofPSAD from 14 requiring adjustment their baseline risk 
All: enlarged DRE 50%) vs PSAD ~ PSA/vol to 30% for finasteride tx Also not clear 
LUTS placebo Sn=% cancers Using PSA alone with criterion for when 
Excl: PSA >40, X 12 with PSAD >0.1 cutoff of lOng/ml at biopsy; no end of 
UTI, chronic months Sp=% no cancer baseline and 5 ng/ml study biopsy to 
prostatitis, with PSA <0.1 after 12 months of minimize bias 
neurogenic bladder PPV%with fmasteride tx produces 
PSAD>O.l and similar Sn and Sp 
dx with cancer 
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Key Question 4-6: Abstraction Table 
!
Outcome: person-years saved (PYS) Weighted 
outcomes to evaluate risk-benefit 
we;ohts assigned based on survival (easy & accurate) 
SEER survival data for men >55 with low/int 
and high grade tumors 
survival for gen population from National Center 
Health Statistics 
!Assumed: if cancer prevented, followed normal life-
under survival curves = avg survival time 
lwe;oht ofHG ~ (AUCprev-AUChg)/(AUCprev-
person years lived (PYL) ~cohort size x AUC 
of weights for each outcome 
all men with CaP between 1993-1997 
data: 1000 men aged 63 (mean loositive 
age) - 6% (or 60) would get 
over 7 yrs; and 20% get Gleason lmortalitv 
-only 45 get cancer over 7 
but 
change in rate of high-grade: 
16,760 PYS over 10 yrs 
!
Assume from PCPT 6.9% increase 
relative to normal cohort 
PYS over 10 yrs 
!
Assume 8.9% diff (graded only) 
246,859 PYS over 10 yrs 
rate ofHG would have to be 
higher than normal for risks to ~ 
survival 
IDecision-a~alysis Assumes men ;,eet PCPT entry criteria (age and low Benefit for finast tx popn with WW: 
risk of CaP) <1 month (-0.4 months in 55-59, +0.8Ibenefits: 
Probability of cancer detection taken from PCPT in 65-69) 
Assumed that patients with no cancer survived entire Benefit for finast tx popn with RP 
years (overestimates) 1.7 month (0.7 RFS) 
!Survival estimates based on published cohort data with Assume no gleason effect: 
or more survival after RP or WW ... NOT XRT 3 month CSS- regardless ofWW/RPieffect 
!Studies included did not have overall survival data: had For-cause subset tx RP: 
mets-free survival etc. 0.35 month survival in 15yr CSS 
!
Modelled variability: by using LCI and UCI of95% CI 0.09 month survival in 15yr RFS 
around RRR from PCPT (24.8%) For-cause subset tx WW: 
month decrease in younger 
month increase in older 
scores equiv: 0.7 month 
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!system: used 
-more 
to 
!incidence rates 
!advantage to 
Benefit of finast increases with XR T or brachy 
increasing incidence of CaP in gen outcomes not 
popn modelled. 
Estimates based 
on PFS and MFS 
Only 15 yrs 
Unger et al; 2005 Identical model as presented above- essentially a 
Person-years repeat publication. 
saved modelling 
?Repeat 
Klein et al; 2005 Absolute benefit/absolute risk ratio calculated Overall; 4.6:1 Finasteride Quality -fair Absolute risk 
Benefit: risk Used: ratio of absolute risk reduction: absolute excess -meaning 4.6 cancers prevented for ranges from - Weights not increase for 
ratios risk of excess high-grade cancers every 1 excess case of high-grade being beneficial assigned to each grade: they used 
Altered assumptions: 10,25, 50% of excess was disease to more outcome only graded 
artefact -Delta % artefact: beneficial -biased reporting tumors rather 
Altered assumptions: 25% overdetection in finasteride 10%~5.1:1 depending on and modelling by than the ARR for 
arm 25% ~ 6.2:1 degree of grade not using for- all men in the 
Repeated analysis for-cause biopsies 50%~ 9.2:1 bias and cause biopsy study: therefore 
-assuming 25% over detection: overdetection -all assumptions underestimates? 
0%~ 8.2:1 positively shed 
10% ~ 9.1:1 light on fmast 
25% ~ 10.9:1 -conflicts of 
50%~ 16.3:1 interest: Merk++ 
-For-cause: only ranges from 1.9:1-
8.0:1 
Grover et al; Montreal prostate cancer model: a markov model Base cohort tx with finast: PCPT results Quality - good No costs 
2006 Used to forecast survival Increased survival 140 life years look prontising But didn't weight incorporated 
Markov c Life Estimates expected age at Dx, probability of (0.14 years/person) in terms of value to cancers (wasn't the goal 
Years progression, and overall survival, MFS, DSS Benefit of finasteride decreases with benefit, but not detected vs though ... decisio 
Base case: cohort 1000, 62 yr old men tx c finast increasing age caution grade cancers detected n analysis model: 
Modelled primary tx, salvage tx options based on data Assume grade diff is artefact: and over- and treatment 
from medicare patients 200 life years (0.2 years /person) detection issue 
!Progression rates from published data Model only for-cause biopsy: 
Rates based on PCPT for-cause and EOS biopsies 20 life years (0.02 yrs/person) 
Zeliadt et al; Models cost per life-year and cost per QALY Base-case analysis: Cost burden Quality - good Most elegant of 
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Zoomerang 
Prostate Diseases Survey 
1 
1 
To help tailor this survey, please indicate which of the following best 
describes your practice?( Choose 1) 
Family Practice 
General Internal Medicine 
Geriatrics 
Urology 
Other, Please Specify 
Survey Page l 
Prostate Diseases Survey 
I 
Survey Progress 
http://www.zoomerang.com/members/print_ survey_ body.zgi?ID=L22NWCBGSZUH 
Page 1 of21 
7/13/2006 
Zoomerang 
We are interested in how you diagnose and treat a common prostatic disease 
like Benign Prostatic Hyperplasia (BPH). 
2 
3 
4 
How frequently do you diagnose benign prostatic hyperplasia (BPH) in 
your male patients? (Choose 1) 
I've never diagnosed it 
Only a few times in my career 
About once a year 
Two or three times a year 
About once a month 
Two to three times a month 
About once a week 
More than once a week 
How frequently do you ask about lower urinary tract symptoms (e.g., 
hesitancy, nocturia, weak stream) in your male patients? (Choose 1) 
Never 
Occasionally 
Most of the time 
Always 
Only after they have brought it up first 
How frequently do you calculate American Urological Association (AUA) 
symptom scores or International Prostate Symptom Scores (IPSS) on 
your patients who complain about lower urinary tract symptoms? 
http://www.zoomerang.com/members/print survey body.zgi?ID=L22NWCBGSZUH 
Page 2 of21 
7/13/2006 
Zoomerang 
5 
6 
7 
(Choose 1) 
Never 
Occasionally 
Most of the time 
Always 
If you calculate AUA or IPSS scores, do you use a pre-printed score 
sheet to help you? (Choose 1) 
I never calculate AUA or IPSS scores 
II Yes 
No 
Sometimes 
How frequently do you obtain PSA levels in patients you suspect have 
BPH? (Choose 1) 
Never 
Occasionally 
Most of the time 
II Always 
How frequently do you TREAT men with BPH? (Choose 1) 
II I've never treated it 
Only a few times 
About once a year 
http://www .zoomerang.cornlmembers/print_ survey_ body.zgi?ID=L22NWCBGSZUH 
Page 3 of21 
7/13/2006 
Zoornerang 
9 
10 
Two or three times a year 
About once a month 
Two to three times a month 
About once a week 
More than once a week 
How would you describe your comfort level in treating men with BPH? 
(Choose 1) 
Very comfortable 
Somewhat comfortable 
Somewhat uncomfortable 
Very uncomfortable 
How frequently do you refer your male patients with BPH to a 
specialist? (Choose 1) 
Never 
Occasionally 
Most of the time 
Always 
If you refer patients with BPH, which specific patients are you most 
likely to refer? (Choose all that apply) 
I never refer patients with BPH 
Men with BPH and large prostate glands {>40 ml or golf-ball size) 
http://www.zoornerang.com/rnernbers/print survey body.zgi?ID=L22NWCBGSZUH 
Page 4 of21 
7113/2006 
Zoomerang 
11 
12 
Men with BPH and high PSA levels 
Men with BPH that haven't responded to initial medical therapy 
Men with BPH and concerns about prostate cancer 
Other, Please Specify 
Which of the following are effective in treating BPH? (Choose all that 
apply) 
Non-selective alpha blockers (e.g., doxazosin (Cardura)) 
Selective alpha blockers (e.g., tamsulosin (Fiomax)) 
5-alpha-reductase inhibitors (e.g., finasteride (Proscar)) 
NSAIDs (e.g., Ibuprofen) 
Other, Please Specify 
Is BPH a risk factor for prostate cancer? (Choose 1) 
Yes. BPH is a strong risk factor 
Yes, BPH is a weak risk factor 
IB BPH is not a risk factor 
IB BPH protects against prostate cancer 
Survey Page 2 
http://www .zoomerang.com/members/print_ survey_ body.zgi?ID= L22NWCBGSZUH 
Page 5 of21 
7113/2006 
Zoomerang 
Prostate Diseases Survey 
Survey Progress 
In this section, we are interested in how you treat a common prostate disease 
like Benign Prostatic Hyperplasia (BPH). 
13 
14 
How frequently do you prescribe an alpha-blocker to treat BPH? 
(Choose 1) 
I've never prescribed it 
Only a few times in my career 
About once a year 
Two or three times a year 
About once a month 
Iii Two to three times a month 
About once a week 
More than once a week 
If you use alpha-blockers to treat BPH, which do you favor? 
Iii Non-selective: doxazosin (Cardura); terazosin (Hytrin); prazosin 
(Minipress) 
http://www.zoomerang.com/members/print survey body.zgi?ID=L22NWCBGSZUH 
Page 6 of21 
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15 
16 
Selective: tamsulosin (Fiomax); alfuzosin (Uroxatral) 
Depends on the patient 
I never use alpha-blockers to treat BPH 
Compared to 5 years ago, how frequently do you prescribe alpha-
blockers? (Choose 1) 
More frequently than 5 years ago 
Less frequently than 5 years ago 
About the same 
I never use alpha-blockers to treat BPH 
Other, Please Specify 
If your prescribing patterns have changed what has influenced you? 
(Check all that apply) 
My prescribing patterns have not changed 
Results of the Prostate Cancer Prevention trial (PCPT) -
Finasteride vs Placebo in preventing prostate cancer 
Results of the Medical Therapy of Prostate Symptoms trial 
(MTOPS)- Doxazosin vs Finasteride vs Doxazosin & Finasteride 
vs Placebo in treating BPH symptoms 
The VA Pharmacy Benefits Management Guideline for 
Combination Alpha-Blocker and Finasteride Therapy for BPH 
American Urological Association guidelines for treating BPH 
My colleagues' opinions 
Information presented at continuing medical education 
conferences 
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Other, Please Specify 
Prostate Diseases Survey 
I 
Survey Progress 
In this section we are interested in how you use the 5-alpha reductase inhibitors 
finasteride (Proscar) or dutasteride (Avodart) with your patients. 
17 
Currently, how frequently do you prescribe finasteride or dutasteride? 
(Choose 1) 
• I've never prescribed it 
• I've prescribed it only a few times in my career 
• About once a year 
• Two or three times a year 
• About once a month 
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19 
Two to three times a month 
About once a week 
More than once a week 
Compared to 5 years ago, how frequently do you prescribe finasteride 
or dutasteride? (Choose 1) 
More frequently than 5 years ago 
Less frequently than 5 years ago 
About the same 
I've never prescribed finasteride 
If your prescribing patterns have changed, what has influenced you? 
(Check all that apply) 
My prescribing patterns have not changed 
Results of the Prostate Cancer Prevention trial (PCPT) -
finasteride vs Placebo in preventing prostate cancer 
Results of the Medical Therapy of Prostate Symptoms trial 
(MTOPS)- doxazosin vs finasteride vs doxazosin & finasteride vs 
placebo in treating BPH symptoms 
The VA Pharmacy Benefits Management Guideline for 
Combination Alpha-Blocker and Finasteride Therapy for BPH 
American Urological Association guidelines for treating BPH 
My colleagues' opinions 
Information presented at continuing medical education 
conferences 
Interactions with pharmaceutical representatives 
Other, Please Specify 
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21 
For each indication, please choose how frequently you prescribe 
finasteride or dutasteride? 
Never 
2 3 Tw~ or 5 Tw~ or 7 More8than 
Only a few About once three times About once three times About once once a 
times a year a month a week week a year a month 
Men with BPH regardless of prostate size 
Men with BPH AND small to medium sized prostates 
Men with BPH AND large sized prostates (>40ml or a golf-ball size) 
Men WITHOUT BPH but with concerns regarding prostate cancer 
prevention 
Men with BOTH BPH and concerns regarding prostate cancer 
prevention 
When you use finasteride or dutasteride to treat BPH, how frequently do 
you pair it with an alpha-blocker? (Choose 1) 
I ALWAYS use finasteride or dutasteride in combination with an 
alpha-blocker 
I SOMETIMES use finasteride or dutasteride in combination with 
an alpha-blocker 
I RARELY use finasteride or dutasteride in combination with an 
alpha-blocker 
I use finasteride or dutasteride only as monotherapy 
I never prescribe finasteride or dutasteride 
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Prostate Diseases Survey 
Survey Progress 
Next we are interested in your awareness of the effects of finasteride. 
22 
Which of the following THERAPEUTIC EFFECTS are most frequently 
associated with men taking finasteride? (Choose all that apply) 
Finasteride has no discernible therapeutic effects 
Delaying/preventing progression of BPH 
Improving urinary fiow rates 
Reducing acute urinary retention events 
Reducing urinary incontinence 
Reducing urinary tract infections 
Reducing the need for BPH surgery (e.g., TURP) 
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24 
I don't know 
Other, Please Specify 
Which of the following SIDE-EFFECTS are most frequently associated 
with finasteride? (Choose all that apply) 
Dizziness 
Erectile dysfunction 
Decreased libido 
Abnormal ejaculation 
Postural hypotension 
Peripheral edema 
Dyspnea 
Fatigue/Weakness 
I don't know 
What effect does finasteride have on PSA LEVELS? (Choose 1) 
No effect on PSA levels 
Decreases PSA only slightly 
Decreases PSA by approximately half 
1111 Increases PSA only slightly 
1111 Increases PSA by approximately double 
1111 I don't know 
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26 
27 
What effect does finasteride have on PROSTATE CANCER RISK? 
No effect on prostate cancer risk 
Decreases prostate cancer risk, but only slightly 
Decreases prostate cancer risk, by 25% 
Increases prostate cancer risk, but only slightly 
Increases prostate cancer risk by 25% 
I don't know 
Over what TIME-COURSE does finasteride influence these parameters 
(PSA, prostate volume, symptoms)? (Choose 1) 
Finasteride does NOT influence these parameters 
Days 
Less than 1 month 
Greater than 1 month, but less than 1 year 
Over 1 year 
I don't know 
Does finasteride influence the GLEASON GRADE of prostate cancer? 
(Choose 1) 
NO, the grade of cancers seen in men taking finasteride is the 
same as those who are not taking it. 
i8 YES, the grade of cancers seen is HIGHER 
i8 YES, the grade of cancers seen is LOWER 
i8 I don't know 
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28 
Other, Please Specify 
To whom do you look for recommendations regarding chemoprevention 
for prostate cancer? (Choose all that apply) 
I do not actively search for recommendations 
Colleagues in my local area (i.e., hospital/practice group) 
American Urological Association (AUA) 
American Cancer Society (ACS) 
National Cancer Institute (NCI) 
National Comprehensive Cancer Network (NCCN) 
National Institute of Health (NIH) 
U.S. Preventive Services Task Force (USPSTF) 
Other, Please Specify 
Page 14 of21 
Survey Page 5 
Prostate Diseases Survey 
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In this section, we are asking about your use of finasteride as a prostate cancer 
chemopreventive agent. 
29 
30 
How frequently do your male patients ask you about chemoprevention 
for prostate cancer? (Choose 1) 
Never 
Only happened a few times 
About once a year 
Two to three times a year 
About once a month 
Two to three times a month 
About once a week 
More than once a week 
Do you raise the issue of using finasteride as a prostate cancer 
chemopreventive agent with your patients? {Choose 1) 
Never 
Occasionally 
Most of the time 
Always 
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32 
If a patient comes to you asking about finasteride for chemoprevention 
what issues do you discuss with them? (Choose all that apply} 
I don't discuss the issue with my patients 
I don't discuss the issue, but I refer them to another physician for 
this discussion 
Potential to prevent prostate cancer 
Potential to cause side-effects 
Potential to improve urinary symptoms (if present) 
Potential to alter PSA level 
Potential to induce/select increased grade tumors 
Other, Please Specify 
If you offer finasteride as a prostate cancer chemopreventive agent, IN 
WHICH PATIENTS do you choose to do this? {Choose all that apply} 
I don't offer finasteride as a chemopreventive agent 
I offer it to all male patients 
Men with a family history of prostate cancer 
African American men 
Men with elevated PSA 
Men with moderate to severe urinary symptoms from BPH 
Men with a previous negative prostate biopsy 
Other, Please Specify 
http://www.zoomerang.com/members/print survey body.zgi?ID=L22NWCBGSZUH 
Page 16 of21 
7113/2006 
Zoomerang 
33 
34 
If you DO NOT prescribe finasteride for prostate cancer prevention, 
please rank your reasons in order of importance: (1 = most important, 
5=1east important) 
NOTE: You may skip this question if you DO prescribe finasteride as a 
chemopreventive agent. 
2 3 4 
I did not know it could be used for chemoprevention 
Side effects of finasteride 
Lack of comfort/familiarity with finasteride 
Risk of increased Gleason grade cancers among those taking 
finasteride 
Effects of finasteride on PSA levels 
5 
How do you change your screening practices for prostate cancer among 
your patients who are taking finasteride? (Check all that apply) 
• I don't. I screen men on finasteride the same as those who are 
not taking it 
I check their PSA more frequently 
I use a HIGHER PSA threshold to determine the need for further 
evaluation in men taking finasteride as compared to those who 
are not taking it 
I use a LOWER PSA threshold to determine the need for further 
• evaluation in men taking finasteride as compared to those who 
are not taking it 
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I don't routinely screen for prostate cancer 
Ill Other, Please Specify 
What is your overall assessment of the BALANCE BETWEEN 
BENEFITS AND RISKS of using finasteride as a chemopreventive 
agent for prostate cancer? (Choose 1) 
Mostly positive - benefits outweigh the risks 
Neutral - benefits equal risks 
Mostly negative - risks outweigh the benefits 
I do not have an opinion 
Other, Please Specify 
Page 18 of21 
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Survey Progress 
Finally, please tell us about yourself. 
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37 
38 
39 
What is your age? 
Less than 30 
30-40 
41-50 
51-65 
Over 65 
Gender: 
Female 
Male 
In what STATE do you practice? (Choose 1 from the drop-down menu) 
How much time do you spend seeing patients in a VA facility? (Choose 
1) 
20% or less 
21-40% 
• 41-60% 
• 61-80% 
• >80% 
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41 
42 
43 
Where do you see patients other than in a VA facility? (Choose 1) 
An academic practice setting 
A community (non-academic) practice setting 
Both 
I see patients only in a VA facillity 
In what setting is the majority of your practice conducted? (Choose 1) 
Large city (pop >100,000) 
Suburb of large city 
Town or city (pop 50,000-100,000) 
Town or city (pop 10,000-50,000) 
1M Town (pop <10,000) 
Rural 
Other, Please Specify 
Which of the following do you consider your main practice setting? 
Office or clinic- NOT at a hospital 
1M Office or clinic- AT a hospital 
Hosptial - in-patient 
Approximately what percent of your male patients are African 
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American? 
<20% 
20-40% 
41-60% 
>60% 
Approximately what percent of your male patients are over the age of 
50? (Choose 1) 
<20% 
20-40% 
41-60% 
>60% 
http:/ /www.zoomerang.com/members/print_ survey_ body.zgi?ID=L22NWCBGSZUH 
Page 21 of21 
7 
7/13/2006 
[. 
I!! 
r 
2005 Models 55 year old men: being finast or no tx Tx finast ~ 6 life-years and 46 substantial But did not the 5 studies, 
Markov c QAL Y 5 states: cancer-free, low-grade, high grade, death due QAL Y s gain per I 000 men Benefit small model the side- addresses 
to CaP, and death due to other causes -$1,660,000 per life-year Releaized yrs effects of weakness in the 
For cancer free state: risk of progressing to LG CaP or -$200,000 per QAL Y after treatment finasteride other studies. 
HG CaP based on incidence in gen popn -only men who live beyond 80 Surival data (erectile 
Those treated: grade distribution modified by PCPT benefit from having low-grade beyond I 0 yrs dysfunction etc) 
ratio ofHG to LG tumors prevented are based on pre-
~ o Tx: modelled after SEER data -Assume grade cliff is artefact PSA data: ?not 
Drug costs modelled from 55->85 or first Dx of CaP -40 life years gained per 1000 men at accurate 
Also modelled benefit of reduced BPH with finast $233,000 per life-year QAL Y analysis: 
Accounted for psych value of diagnosis and treatment -Sn Analysis: if RR of high grade limited data 
tumors increases to 1.8 (9% to 12% based on utility 
in fmast arm): benefit is eliminated in prostate-
-Grade is most influential parameter related 
-For QAL Y: most influential is effect conditions 
offinast on BPH, disutility ofBPH 
"willingness to pay threshold: 
100,000 per QALY: finast not cost 
effective 
-Cost of finast would have to drop 
50% to get 100,000 per QAL Y and 
80% to get 100,000 per life-year 
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